MD1367B2 - Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom - Google Patents

Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom

Info

Publication number: MD1367B2
Authority: MD; Moldova
Prior art keywords: administration; cells; cells lymphoma; hybridoma; antibody
Prior art date: 1992-11-13

Application number

MD95-0311A

Other languages

English (en)

Other versions

MD1367C2 (ro

Inventor

Darrell R Anderson

Nabil Hanna

John E Leonard

Roland A Newman

Mitchell E Reff

William H Rastetter

Original Assignee

Idec Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-13

Filing date

1993-11-12

Publication date

1999-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26846468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD1367(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-11-03 Priority claimed from US08/149,099 external-priority patent/US5736137A/en

1993-11-12 Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp

1999-12-31 Publication of MD1367B2 publication Critical patent/MD1367B2/ro

2000-11-30 Publication of MD1367C2 publication Critical patent/MD1367C2/ro

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Lubrication Of Internal Combustion Engines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Luminescent Compositions (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Signal Processing For Digital Recording And Reproducing (AREA)
Steroid Compounds (AREA)

MD95-0311A 1992-11-13 1993-11-12 Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. MD1367C2 (ro)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97889192A	1992-11-13	1992-11-13
US08/149,099 US5736137A (en)	1992-11-13	1993-11-03	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PCT/US1993/010953 WO1994011026A2 (en)	1992-11-13	1993-11-12	Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma

Publications (2)

Publication Number	Publication Date
MD1367B2 true MD1367B2 (ro)	1999-12-31
MD1367C2 MD1367C2 (ro)	2000-11-30

Family

ID=26846468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MD95-0311A MD1367C2 (ro)	1992-11-13	1993-11-12	Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.

Country Status (23)

Country	Link
US (8)	US5843439A (ro)
EP (3)	EP1005870B1 (ro)
JP (3)	JP3095175B2 (ro)
AT (2)	ATE139900T1 (ro)
AU (1)	AU688743B2 (ro)
BG (1)	BG62386B1 (ro)
CA (1)	CA2149329C (ro)
DE (3)	DE69303494T2 (ro)
DK (2)	DK0752248T3 (ro)
ES (2)	ES2152483T3 (ro)
FI (1)	FI112033B (ro)
GR (2)	GR3020731T3 (ro)
LU (1)	LU91089I2 (ro)
LV (1)	LV11732B (ro)
MD (1)	MD1367C2 (ro)
NL (1)	NL300156I2 (ro)
NO (4)	NO321137B1 (ro)
NZ (1)	NZ258392A (ro)
PL (2)	PL174494B1 (ro)
PT (1)	PT752248E (ro)
RO (1)	RO118524B1 (ro)
RU (1)	RU2139731C1 (ro)
WO (1)	WO1994011026A2 (ro)

Families Citing this family (1510)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6190640B1 (en) *	1985-04-19	2001-02-20	Ludwig Institute For Cancer Research	Method for treating neoplasia using humanized antibodies which bind to antigen A33
US7744877B2 (en)	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
DK0752248T3 (da)	1992-11-13	2000-11-13	Idec Pharma Corp	Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
FR2724182B1 (fr) *	1994-09-02	1996-12-13	Pasteur Institut	Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
US20030180290A1 (en) *	1995-06-07	2003-09-25	Idec Pharmaceuticals Corporation	Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
AU721129B2 (en)	1996-01-08	2000-06-22	Genentech Inc.	WSX receptor and ligands
US7122636B1 (en)	1997-02-21	2006-10-17	Genentech, Inc.	Antibody fragment-polymer conjugates and uses of same
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
PT971959E (pt)	1997-04-07	2006-05-31	Genentech Inc	Anticorpos humanizados e metodos para formar anticorpos humanizados
KR100816621B1 (ko)	1997-04-07	2008-03-24	제넨테크, 인크.	항-ｖｅｇｆ 항체
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6610293B1 (en)	1997-06-16	2003-08-26	The Henry M. Jackson Foundation For The Advancement Of Military Medicine	Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
ATE410512T1 (de)	1997-11-21	2008-10-15	Genentech Inc	Plättchen-spezifische antigene und deren pharmazeutische verwendung
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
EP1947119A3 (en)	1997-12-12	2012-12-19	Genentech, Inc.	Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
ATE405651T1 (de)	1998-03-17	2008-09-15	Genentech Inc	Zu vegf und bmp1 homologe polypeptide
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
AU740405B2 (en)	1998-05-15	2001-11-01	Genentech Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en)	1998-05-15	2007-12-19	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
WO2001060397A1 (en) *	2000-02-16	2001-08-23	Genentech, Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
ATE443723T1 (de)	1998-06-12	2009-10-15	Genentech Inc	Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
US7250494B2 (en)	1998-06-15	2007-07-31	Biosynexus Incorporated	Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
PT1974747E (pt)	1998-08-11	2012-09-05	Biogen Idec Inc	Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
US6224866B1 (en)	1998-10-07	2001-05-01	Biocrystal Ltd.	Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US20010033839A1 (en) *	1999-10-04	2001-10-25	Emilio Barbera-Guillem	Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
US6410319B1 (en)	1998-10-20	2002-06-25	City Of Hope	CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
HK1041811A1 (zh) *	1998-11-09	2002-07-26	Idec药物公司	接受bmt或pbsc移植患者的抗cd20嵌合抗体治疗
ES2543819T3 (es) *	1998-11-09	2015-08-24	Biogen Inc.	Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
EP1950300A3 (en)	1998-11-18	2011-03-23	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
EP2075335A3 (en)	1998-12-22	2009-09-30	Genentech, Inc.	Methods and compositions for inhibiting neoplastic cell growth
PL209392B1 (pl)	1999-01-15	2011-08-31	Genentech Inc	Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US20020102208A1 (en) *	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) *	1999-03-03	2001-03-27	Idec Pharmaceuticals Corporation	Regioselective synthesis of DTPA derivatives
WO2000067796A1 (en)	1999-05-07	2000-11-16	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US8119101B2 (en) *	1999-05-10	2012-02-21	The Ohio State University	Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) *	1999-05-10	2010-11-09	Immunomedics, Inc.	Anti-CD74 immunoconjugates and methods
US8383081B2 (en)	1999-05-10	2013-02-26	Immunomedics, Inc.	Anti-CD74 immunoconjugates and methods of use
US7312318B2 (en) *	2002-03-01	2007-12-25	Immunomedics, Inc.	Internalizing anti-CD74 antibodies and methods of use
DE60042785D1 (de) *	1999-06-09	2009-10-01	Immunomedics Inc	Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
DE60043367D1 (de)	1999-06-15	2009-12-31	Genentech Inc	Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
CN100340575C (zh)	1999-06-25	2007-10-03	杰南技术公司	人源化抗ErbB2抗体及其在制备药物中的应用
KR20020027490A (ko) *	1999-07-12	2002-04-13	제넨테크, 인크.	Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
AU2005211669C1 (en) *	1999-08-11	2017-09-21	F. Hoffmann-La Roche Ag	Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en)	1999-08-11	2002-09-17	Idec Pharmaceuticals Corporation	Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) *	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU784971B2 (en) *	1999-08-11	2006-08-10	Biogen Inc.	Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
EP2264070A1 (en) *	1999-08-11	2010-12-22	Biogen-Idec Inc.	Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody
EP1918305A1 (en) *	1999-08-11	2008-05-07	Biogen Idec Inc.	New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
KR20110008112A (ko)	1999-08-27	2011-01-25	제넨테크, 인크.	항-ＥｒｂＢ2 항체 투여 치료 방법
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2491433A1 (en)	1999-12-01	2001-06-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1897945T3 (da)	1999-12-23	2012-05-07	Genentech Inc	IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
CA2397207C (en)	2000-01-13	2013-12-03	Genentech, Inc.	Novel stra6 polypeptides
US20030185796A1 (en) *	2000-03-24	2003-10-02	Chiron Corporation	Methods of therapy for non-hodgkin's lymphoma
WO2004043361A2 (en)	2002-11-08	2004-05-27	Genentech, Inc.	Compositions and methods for the treatment of natural killer cell related diseases
JP2003531588A (ja)	2000-04-11	2003-10-28	ジェネンテック・インコーポレーテッド	多価抗体とその用途
AU2001259142C1 (en) *	2000-04-25	2006-11-23	Biogen Idec Inc.	Intrathecal administration of rituximab for treatment of central nervous system lymphomas
AU6531101A (en)	2000-06-02	2001-12-17	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004512262A (ja)	2000-06-20	2004-04-22	アイデック　ファーマスーティカルズ　コーポレイション	非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
JP2003535908A (ja) *	2000-06-22	2003-12-02	アイデックファーマスーティカルズコーポレイション	二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法
EP2275549A1 (en)	2000-06-23	2011-01-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648046A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2412493C (en) *	2000-06-26	2010-11-09	Wellstat Biologics Corporation	Purging of cells using viruses
AU6461201A (en) *	2000-07-12	2002-01-21	Idec Pharma Corp	Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
DE60136816D1 (de)	2000-07-27	2009-01-15	Genentech Inc	Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
ATE412009T1 (de)	2000-08-24	2008-11-15	Genentech Inc	Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en)	2000-09-01	2008-09-17	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004508420A (ja) *	2000-09-18	2004-03-18	アイデック　ファーマスーティカルズ　コーポレイション	Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
AU2002213357A1 (en) *	2000-10-20	2002-05-06	Idec Pharmaceuticals Corporation	Variant igg3 rituxan r and therapeutic use thereof
ATE338124T1 (de)	2000-11-07	2006-09-15	Hope City	Cd19-spezifische umgezielte immunzellen
US7408041B2 (en)	2000-12-08	2008-08-05	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040002450A1 (en) *	2000-12-29	2004-01-01	Janette Lazarovits	Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) *	2000-12-29	2006-11-07	Bio-Technology General (Israel) Ltd.	Specific human antibodies for selective cancer therapy
US20040001839A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
RU2420537C2 (ru) *	2001-01-17	2011-06-10	Трабьон Фармасьютикалз Инк.	Слитые белки связывающий домен-иммуноглобулин
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
NZ527283A (en) *	2001-01-29	2006-03-31	Biogen Idec Inc	Modified antibodies and methods of use
US20020159996A1 (en)	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
AU2007234621B2 (en) *	2001-01-31	2010-08-26	Biogen Idec Inc.	Use of immunoregulatory antibodies in the treatment of neoplastic disorders
CN100574803C (zh)	2001-01-31	2009-12-30	拜奥根Idec公司	免疫调节抗体在治疗肿瘤性疾病中的用途
KR20080087184A (ko)	2001-01-31	2008-09-30	바이오겐 아이덱 인크.	종양질환 치료를 위한 ｃｄ23 길항제의 용도
US20070065436A1 (en) *	2001-01-31	2007-03-22	Biogen Idec Inc.	Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) *	2001-11-09	2003-06-05	Kandasamy Hariharan	Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) *	2002-01-31	2003-11-13	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
WO2002069232A2 (en)	2001-02-19	2002-09-06	Merck Patent Gmbh	Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
IL157946A0 (en) *	2001-04-02	2004-03-28	Genentech Inc	Combination therapy
AU2002307037B2 (en) *	2001-04-02	2008-08-07	Biogen Idec Inc.	Recombinant antibodies coexpressed with GnTIII
US20020193569A1 (en) *	2001-06-04	2002-12-19	Idec Pharmaceuticals Corporation	Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
PT2000545E (pt)	2001-06-20	2011-12-21	Genentech Inc	Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
BR0211614A (pt) *	2001-08-03	2006-10-31	Genentech Inc	polipeptìdeo tacis e br3 e empregos dos mesmos
NZ571596A (en)	2001-08-03	2010-11-26	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6658260B2 (en)	2001-09-05	2003-12-02	Telecommunication Systems, Inc.	Inter-carrier short messaging service providing phone number only experience
DE60238143D1 (de)	2001-09-18	2010-12-09	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
JP4424987B2 (ja) *	2001-09-20	2010-03-03	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
RU2201254C1 (ru) *	2001-09-25	2003-03-27	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
MXPA04004634A (es)	2001-11-16	2004-08-12	Idec Pharma Corp	Expresion policistronica de anticuerpos.
US20030157641A1 (en) *	2001-11-16	2003-08-21	Idec Pharmaceuticals Corporation	Polycistronic expression of antibodies
AR037756A1 (es)	2001-12-17	2004-12-01	Bayer Corp	Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US20040052779A1 (en) *	2001-12-21	2004-03-18	Stinson Jeffrey R.	Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
AU2002367318B2 (en)	2002-01-02	2007-07-12	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US8071096B2 (en)	2002-01-25	2011-12-06	G2 Therapies Ltd	Anti-C5aR antibodies and uses thereof
CA2473144C (en)	2002-02-05	2013-05-28	Genentech, Inc.	Protein purification
WO2003068821A2 (en) *	2002-02-14	2003-08-21	Immunomedics, Inc.	Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en)	2002-02-14	2012-10-16	Immunomedics, Inc.	Structural variants of antibodies for improved therapeutic characteristics
WO2003072736A2 (en)	2002-02-21	2003-09-04	Duke University	Reagents and treatment methods for autoimmune diseases
EP1575480A4 (en)	2002-02-22	2008-08-06	Genentech Inc	COMPOSITIONS AND METHODS OF TREATING IMMUNE-INFLAMMATORY DISEASES
SI1485477T1 (sl)	2002-02-25	2009-10-31	Genentech Inc	Novi citokinski receptor GLM-R tipa 1
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en)	2002-03-01	2017-09-26	Immunomedics, Inc.	Anti-Trop-2 antibody-drug conjugates and uses thereof
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US8658773B2 (en)	2011-05-02	2014-02-25	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
NZ535425A (en)	2002-03-13	2008-05-30	Biogen Idec Inc	Anti-alphavbeta6 antibodies
US20030180292A1 (en) *	2002-03-14	2003-09-25	Idec Pharmaceuticals	Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP2289942B1 (en)	2002-04-10	2013-07-31	Genentech, Inc.	Anti-HER2 antibody variants
JP2005536190A (ja)	2002-04-16	2005-12-02	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
EP2305710A3 (en)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetic antibody phage libraries
US20040208877A1 (en) *	2002-07-01	2004-10-21	Avigdor Levanon	Antibodies and uses thereof
US20040202665A1 (en) *	2002-07-01	2004-10-14	Janette Lazarovits	Compositions and methods for therapeutic treatment
WO2004004649A2 (en)	2002-07-08	2004-01-15	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
WO2004004661A2 (en) *	2002-07-09	2004-01-15	Point Therapeutics, Inc.	Boroproline compound combination therapy
WO2004008099A2 (en)	2002-07-15	2004-01-22	Genentech, Inc.	METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2004011611A2 (en) *	2002-07-25	2004-02-05	Genentech, Inc.	Taci antibodies and uses thereof
US20040171809A1 (en)	2002-09-09	2004-09-02	Korsmeyer Stanley J.	BH3 peptides and method of use thereof
JP5401001B2 (ja)	2002-09-11	2014-01-29	ジェネンテック，インコーポレイテッド	免疫関連疾患の治療のための新規組成物と方法
EP1578373A4 (en)	2002-09-11	2007-10-24	Genentech Inc	NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
US20070010434A1 (en)	2002-09-16	2007-01-11	Genetech, Inc.	Novel compositions and methods for the treatment of immune related diseases
CA2499843A1 (en)	2002-09-25	2004-04-08	Genentech, Inc.	Novel compositions and methods for the treatment of psoriasis
EP1553975B8 (en)	2002-09-27	2023-04-12	Xencor, Inc.	Optimized fc variants and methods for their generation
BRPI0315295C1 (pt) *	2002-10-17	2021-05-25	Genmab As	anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
EP2322200A3 (en)	2002-10-29	2011-07-27	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
JP2011516026A (ja)	2002-11-26	2011-05-26	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための組成物と方法
US8420086B2 (en)	2002-12-13	2013-04-16	Immunomedics, Inc.	Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
TWI335821B (en) *	2002-12-16	2011-01-11	Genentech Inc	Immunoglobulin variants and uses thereof
US7534427B2 (en) *	2002-12-31	2009-05-19	Immunomedics, Inc.	Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2248892B1 (en)	2003-01-22	2015-04-22	Roche Glycart AG	Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
KR20050102627A (ko) *	2003-01-27	2005-10-26	바이오겐 아이덱 엠에이 인코포레이티드	Ｉｇｓｆ9 및 ｌｉｖ-1을 사용한 암 치료용 조성물 및치료방법
WO2004070011A2 (en)	2003-02-01	2004-08-19	Tanox, Inc.	HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
GB0304576D0 (en) *	2003-02-28	2003-04-02	Lonza Biologics Plc	Protein a chromatography
US20090010920A1 (en)	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
MXPA05010555A (es)	2003-04-04	2006-03-09	Genentech Inc	Formulaciones de proteina y anticuerpo de alta concentracion.
EP1613350B1 (en) *	2003-04-09	2009-03-18	Genentech, Inc.	Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
WO2004101756A2 (en)	2003-05-09	2004-11-25	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
CN1802388B (zh) *	2003-05-09	2011-01-05	杜克大学	Cd20特异抗体及使用它们的方法
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
JP4745242B2 (ja) *	2003-05-20	2011-08-10	アプライドモレキュラーエボリューション，インコーポレイテッド	Ｃｄ２０結合分子
UA101945C2 (uk)	2003-05-30	2013-05-27	Дженентек, Инк.	Лікування злоякісного новоутворення за допомогою бевацизумабу
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
JP2007526220A (ja)	2003-06-05	2007-09-13	ジェネンテック・インコーポレーテッド	Ｂ細胞疾患の併用療法
WO2005001486A1 (en)	2003-06-06	2005-01-06	Genentech, Inc.	Modulating the interaction between hgf beta chain and c-met
US20040254108A1 (en) *	2003-06-13	2004-12-16	Jing Ma	Preparation and application of anti-tumor bifunctional fusion proteins
US20050232931A1 (en) *	2003-06-13	2005-10-20	Oncomax Acquisition Corp.	Preparation and application of anti-tumor bifunctional fusion proteins
US20050069955A1 (en) *	2003-06-30	2005-03-31	Daniel Plaksin	Antibodies and uses thereof
US20050266009A1 (en) *	2003-06-30	2005-12-01	Savient Pharmaceuticals, Inc.	Antibodies and uses thereof
US20050152906A1 (en) *	2003-06-30	2005-07-14	Avigdor Levanon	Specific human antibodies
KR20060041205A (ko)	2003-07-01	2006-05-11	이뮤노메딕스, 인코오포레이티드	양특이성 항체들의 다가 담체들
EP2784084B2 (en)	2003-07-08	2023-10-04	Novartis Pharma AG	Antagonist antibodies to IL-17A/F heterologous polypeptides
AR046071A1 (es)	2003-07-10	2005-11-23	Hoffmann La Roche	Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US7834155B2 (en) *	2003-07-21	2010-11-16	Immunogen Inc.	CA6 antigen-specific cytotoxic conjugate and methods of using the same
ATE496944T1 (de) *	2003-07-21	2011-02-15	Immunogen Inc	Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
CA2532965C (en)	2003-07-22	2013-05-14	Astex Therapeutics Limited	3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
US20050032130A1 (en) *	2003-07-29	2005-02-10	Genentech, Inc.	Neutralizing antibody assay and uses therefor
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US8147832B2 (en) *	2003-08-14	2012-04-03	Merck Patent Gmbh	CD20-binding polypeptide compositions and methods
MXPA06002134A (es) *	2003-08-29	2006-05-31	Genentech Inc	Terapia de trastornos oculares.
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
WO2005044307A2 (en)	2003-11-04	2005-05-19	Chiron Corporation	Methods of therapy for b cell-related cancers
CN1878568A (zh)	2003-11-05	2006-12-13	盘林京有限公司	Cdim结合抗体的增强的b细胞细胞毒性
US9296820B2 (en)	2003-11-05	2016-03-29	Roche Glycart Ag	Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005047327A2 (en)	2003-11-12	2005-05-26	Biogen Idec Ma Inc.	NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
DK2295073T3 (da)	2003-11-17	2014-07-28	Genentech Inc	Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
WO2005060520A2 (en)	2003-11-25	2005-07-07	Dana-Farber Cancer Institute, Inc.	ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
US7312320B2 (en)	2003-12-10	2007-12-25	Novimmune Sa	Neutralizing antibodies and methods of use thereof
CA2548282A1 (en)	2003-12-11	2005-06-30	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
CN1917901A (zh) *	2003-12-19	2007-02-21	健泰科生物技术公司	自身免疫病疗法中cd20的检测
KR20060107555A (ko) *	2003-12-19	2006-10-13	제넨테크, 인크.	이식 거부에서 ｃｄ20의 검출
PT1718677E (pt)	2003-12-19	2012-07-18	Genentech Inc	Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
SI2311873T1 (sl)	2004-01-07	2018-12-31	Novartis Vaccines And Diagnostics, Inc.	M-CSF-specifična monoklonska protitelesa in njihova uporaba
US8883160B2 (en) *	2004-02-13	2014-11-11	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en)	2004-02-13	2017-01-24	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
AU2005214382B2 (en)	2004-02-19	2011-08-04	Genentech, Inc.	CDR-repaired antibodies
ES2376337T3 (es)	2004-03-03	2012-03-13	Iq Therapeutics Bv	Anticuerpos monoclonales neutralizantes de la toxina del �?ntrax humanos y métodos para su uso.
EP1740615B1 (en)	2004-03-31	2014-11-05	Genentech, Inc.	Humanized anti-tgf-beta antibodies
PT1737891E (pt)	2004-04-13	2013-04-16	Hoffmann La Roche	Anticorpos anti p-selectina
AU2005247303A1 (en) *	2004-04-16	2005-12-08	Genentech, Inc.	Treatment of polychondritis and mononeuritis multiplex with anti-CD20 antibodies
CA2563432A1 (en) *	2004-04-16	2005-12-01	Genentech, Inc.	Method for augmenting b cell depletion
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
ZA200608982B (en) *	2004-05-05	2008-06-25	Genentech Inc	Preventing autoimmune disease by using an anti-CD20 antibody
MXPA06014067A (es) *	2004-06-04	2007-02-15	Genentech Inc	Metodo para tratar lupus.
AU2005249566B2 (en) *	2004-06-04	2010-11-11	Genentech, Inc.	Method for treating multiple sclerosis
GT200500155A (es)	2004-06-16	2006-05-15		Terapia del càncer resistente al platino
KR100984459B1 (ko)	2004-07-02	2010-09-29	제넨테크, 인크.	Ｉａｐ의 억제제
WO2006005477A1 (en) *	2004-07-09	2006-01-19	Schering Ag	Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
EP2471813B1 (en)	2004-07-15	2014-12-31	Xencor, Inc.	Optimized Fc variants
SI1771474T1 (sl)	2004-07-20	2010-06-30	Genentech Inc	Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
DK1771482T3 (da)	2004-07-22	2014-10-20	Genentech Inc	HER2-antistofsammensætning
BRPI0513100A (pt) *	2004-07-22	2007-10-23	Genentech Inc	métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
MX2007001064A (es)	2004-07-26	2007-04-12	Genentech Inc	Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
US20070286855A1 (en) *	2004-08-03	2007-12-13	Mayo Foundation For Medical Education And Research	Improving treatments
AU2005274905B2 (en)	2004-08-04	2010-12-23	Mentrik Biotech, Llc	Variant Fc regions
WO2006026759A2 (en)	2004-09-03	2006-03-09	Genentech, Inc.	Humanized anti-beta7 antagonists and uses therefor
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
DK1791565T3 (en)	2004-09-23	2016-08-01	Genentech Inc	Cysteingensplejsede antibodies and conjugates
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1797430A4 (en) *	2004-10-04	2008-05-14	Yissum Res Dev Co	METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER
BRPI0516297A (pt) *	2004-10-05	2008-09-02	Genentech Inc	métodos de tratamento de vasculite e artigos de fabricação
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
MX2007005361A (es) *	2004-11-05	2008-01-11	Cephalon Inc	Tratamientos para cancer.
AU2005304624B2 (en)	2004-11-12	2010-10-07	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
FR2879204B1 (fr) *	2004-12-15	2007-02-16	Lab Francais Du Fractionnement	Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
DK1836201T4 (da)	2004-12-20	2013-11-11	Genentech Inc	Pyrrolidininhibitorer af IAP.
DE602004021404D1 (de)	2004-12-23	2009-07-16	Gpc Biotech Ag	Quadratsäurederivate mit antiproliferativer Wirkung
EP1838736B1 (en)	2005-01-05	2013-03-06	Biogen Idec MA Inc.	Cripto binding molecules
EP2230517A1 (en)	2005-01-07	2010-09-22	Diadexus, Inc.	OVR110 antibody compositions and methods of use
TW200637574A (en) *	2005-01-13	2006-11-01	Genentech Inc	Treatment method
US8436190B2 (en) *	2005-01-14	2013-05-07	Cephalon, Inc.	Bendamustine pharmaceutical compositions
CN102580084B (zh)	2005-01-21	2016-11-23	健泰科生物技术公司	Her抗体的固定剂量给药
RU2436575C2 (ru) *	2005-01-21	2011-12-20	Астекс Терапьютикс Лимитед	Соединения для использования в фармацевтике
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
MX2007008781A (es)	2005-01-21	2007-09-11	Astex Therapeutics Ltd	Compuestos farmaceuticos.
US8029783B2 (en)	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2597933A1 (en) *	2005-02-15	2006-08-24	Novartis Vaccines And Diagnostics, Inc.	Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
WO2006089141A2 (en)	2005-02-18	2006-08-24	Dana-Farber Cancer Institute	Antibodies against cxcr4 and methods of use thereof
EP1850874B1 (en)	2005-02-23	2013-10-16	Genentech, Inc.	Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US9707302B2 (en)	2013-07-23	2017-07-18	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en)	2015-06-25	2018-08-28	Immunomedics, Inc.	Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CA2603414C (en) *	2005-03-31	2012-09-18	Biomedics Inc.	Anti-cd20 monoclonal antibody
EP2096166A1 (en) *	2005-03-31	2009-09-02	Osaka University	Method for production of antibody directed against cell membrane surface antigen epitope and assaying method
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en)	2005-04-06	2013-07-02	Ibc Pharmaceuticals, Inc.	Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
EP1865981A2 (en)	2005-04-07	2007-12-19	Chiron Corporation	Cacna1e in cancer diagnosis, detection and treatment
CA2604844A1 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics, Inc.	Cancer-related genes
AR053579A1 (es) *	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
ZA200708857B (en) *	2005-04-22	2009-01-28	Genentech Inc	Method for treating dementia or alzheimer's disease with a CD30 antibody
AU2006242154B2 (en) *	2005-05-02	2011-11-03	Cold Spring Harbor Laboratory	Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
EP3263581B2 (en)	2005-05-17	2025-07-09	University of Connecticut	Compositions and methods for immunomodulation in an organism
US7430425B2 (en) *	2005-05-17	2008-09-30	Telecommunication Systems, Inc.	Inter-carrier digital message with user data payload service providing phone number only experience
ZA200709956B (en) *	2005-05-20	2009-02-25	Genentech Inc	Pretreatment of a biological sample from an autoimmune disease subject
BRPI0610203A2 (pt)	2005-05-24	2010-06-01	Avestha Gengraine Tech Pvt Ltd	processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica
GB0510790D0 (en)	2005-05-26	2005-06-29	Syngenta Crop Protection Ag	Anti-CD16 binding molecules
WO2006132788A2 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
WO2007008943A2 (en)	2005-07-08	2007-01-18	Xencor, Inc.	Optimized anti-ep-cam antibodies
CN104072614B (zh)	2005-07-08	2017-04-26	生物基因Ma公司	抗-αvβ6 抗体及其用途
WO2007009469A2 (en)	2005-07-21	2007-01-25	Genmab A/S	Potency assays for antibody drug substance binding to an fc receptor
RU2421242C2 (ru)	2005-07-25	2011-06-20	Трабьон Фармасьютикалз, Инк.	Применение однократной дозы cd20-специфических связывающих молекул
RU2423381C2 (ru) *	2005-07-25	2011-07-10	Трабьон Фармасьютикалз, Инк.	Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
JP5457671B2 (ja)	2005-07-28	2014-04-02	ノバルティスアーゲー	Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
EP1922410A2 (en)	2005-08-15	2008-05-21	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
EP1762575A1 (en) *	2005-09-12	2007-03-14	Ganymed Pharmaceuticals AG	Identification of tumor-associated antigens for diagnosis and therapy
WO2007041635A2 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
AU2006315037C1 (en)	2005-11-18	2013-05-02	Ichnos Sciences SA	Anti-alpha2 integrin antibodies and their uses
EP1962584A2 (en)	2005-11-21	2008-09-03	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
ES2618543T3 (es) *	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
CA2631327C (en)	2005-12-02	2015-10-13	Genentech, Inc.	Her2 binding polypeptides and uses thereof
BRPI0619118A2 (pt)	2005-12-02	2011-09-13	Genentech Inc	composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
WO2007064911A1 (en) *	2005-12-02	2007-06-07	Biogen Idec Inc.	Anti-mouse cd20 antibodies and uses thereof
US8466263B2 (en)	2005-12-02	2013-06-18	Dana-Farber Cancer Institute, Inc.	Carbonic anhydrase IX (G250) anitbodies
CA2633887C (en)	2005-12-15	2015-12-22	Genentech, Inc.	Methods and compositions for targeting polyubiquitin
CN101374829A (zh)	2005-12-19	2009-02-25	健泰科生物技术公司	Iap的抑制剂
BRPI0706840A2 (pt)	2006-01-05	2011-04-05	Genentech Inc	anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
SI1976884T1 (sl)	2006-01-20	2013-04-30	Genetech, Inc.	Anti-efrinB2 protitelesa in postopki uporabe le teh
CA2642419A1 (en)	2006-02-06	2007-08-16	Rhode Island Hospital	Gpr30 estrogen receptor in breast cancers
EP2050335A1 (en)	2006-02-17	2009-04-22	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
EP1999148B8 (en)	2006-03-06	2014-03-05	Medlmmune, LLC	Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2009532336A (ja) *	2006-03-06	2009-09-10	メディミューン，エルエルシー	ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
JPWO2007102200A1 (ja)	2006-03-07	2009-07-23	国立大学法人大阪大学	抗ｃｄ２０モノクローナル抗体
EP1999269B1 (en)	2006-03-08	2014-12-10	Wake Forest University Health Sciences	Soluble monomeric ephrin a1
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
JP2009529915A (ja)	2006-03-20	2009-08-27	ゾーマテクノロジーリミテッド	ガストリン物質に対して特異的なヒト抗体および方法
WO2007109347A2 (en)	2006-03-21	2007-09-27	The Regents Of The University Of California	N-cadherin and ly6 e: targets for cancer diagnosis and therapy
US20100278821A1 (en)	2006-03-21	2010-11-04	The Regents Of The University Of California	N-cadherin: target for cancer diagnosis and therapy
NZ615012A (en)	2006-03-21	2015-11-27	Genentech Inc	Combinatorial therapy involving alpha5beta1 antagonists
RU2008141912A (ru)	2006-03-23	2010-04-27	Новартис АГ (CH)	Противоопухолевые лекарства на основе антител к клеточным антигенам
CA2645853A1 (en)	2006-03-31	2007-11-01	Dana-Farber Cancer Institute	Methods of determining cellular chemosensitivity
AU2007243946B2 (en)	2006-04-05	2012-11-29	Curis, Inc.	Method for using BOC/CDO to modulate hedgehog signaling
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
US20080014203A1 (en)	2006-04-11	2008-01-17	Silke Hansen	Antibodies against insulin-like growth factor I receptor and uses thereof
TW200813231A (en)	2006-04-13	2008-03-16	Novartis Vaccines & Diagnostic	Methods of treating, diagnosing or detecting cancer
EP2011870A4 (en)	2006-04-14	2010-09-15	Medical & Biol Lab Co Ltd	MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
CA2649387A1 (en)	2006-04-19	2008-03-27	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
US7727525B2 (en) *	2006-05-11	2010-06-01	City Of Hope	Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
EP2032606B1 (en)	2006-05-30	2013-11-27	Genentech, Inc.	Antibodies and immunoconjugates and uses therefor
NZ573646A (en)	2006-06-12	2012-04-27	Wyeth Llc	Single-chain multivalent binding proteins with effector function
MX2008015830A (es)	2006-06-30	2009-01-09	Novo Nordisk As	Anticuerpos anti-nkg2a y usos de los mismos.
CN101563105B (zh)	2006-07-10	2013-01-23	拜奥根Idec马萨诸塞公司	用于抑制smad4-缺陷癌症的组合物和方法
ES2479668T3 (es)	2006-07-11	2014-07-24	University Of Medicine And Dentistry Of New Jersey	Proteínas de reparación de la membrana celular, ácidos nucleicos que las codifican y métodos de uso asociados
WO2008008917A2 (en) *	2006-07-12	2008-01-17	Mayo Foundation For Medical Education And Research	Hydroxyapatite particles
CA2659820A1 (en)	2006-08-04	2008-02-14	Novartis Ag	Ephb3-specific antibody and uses thereof
AU2007284651B2 (en)	2006-08-09	2014-03-20	Institute For Systems Biology	Organ-specific proteins and methods of their use
AR064801A1 (es)	2006-08-18	2009-04-29	Xoma Technology Ltd	Anticuerpo especifico prlr (receptor de prolactina) y sus usos
ES2570153T3 (es)	2006-08-22	2016-05-17	Novo Nordisk As	Anticuerpos anti-C5aR con propiedades mejoradas
EP2061900A2 (en)	2006-08-25	2009-05-27	Oncotherapy Science, Inc.	Prognostic markers and therapeutic targets for lung cancer
US8636995B2 (en) *	2006-08-31	2014-01-28	Cardiac Pacemakers, Inc.	Methods and devices to regulate stem cell homing
US20080058922A1 (en) *	2006-08-31	2008-03-06	Cardiac Pacemakers, Inc.	Methods and devices employing vap-1 inhibitors
US8372399B2 (en) *	2006-08-31	2013-02-12	Cardiac Pacemakers, Inc.	Bispecific antibodies and agents to enhance stem cell homing
ES2372217T3 (es)	2006-09-12	2012-01-17	Genentech, Inc.	Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
EP2099467B1 (en)	2006-10-03	2017-05-10	University Of Medicine And Dentistry Of New Jersey	Atap peptides, nucleic acids encoding the same and associated methods of use
US9382327B2 (en)	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
EP2073807A1 (en)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
BRPI0717638A2 (pt)	2006-10-27	2013-11-12	Genentech Inc	Anticorpors e imunoconjugados e usos para os mesmos
KR20090105913A (ko)	2006-11-02	2009-10-07	다니엘 제이 카폰	이동 부분을 갖는 하이브리드 면역글로불린
MX2009005466A (es)	2006-11-22	2009-08-17	Adnexus A Bristol Myers Sqibb	Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
JP5391073B2 (ja)	2006-11-27	2014-01-15	ディアデクサスインコーポレーテッド	Ｏｖｒ１１０抗体組成物および使用方法
WO2008070780A1 (en)	2006-12-07	2008-06-12	Novartis Ag	Antagonist antibodies against ephb3
NZ577150A (en)	2006-12-19	2012-04-27	Genentech Inc	Imidazopyridine inhibitors of iap
EP2111228B1 (en)	2007-02-02	2011-07-20	Bristol-Myers Squibb Company	10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
MX2009008430A (es)	2007-02-09	2009-10-28	Genentech Inc	Anticuerpos anti-robo4 y sus usos.
KR101598229B1 (ko)	2007-02-16	2016-02-26	메리맥 파마슈티컬즈, 인크.	Ｅｒｂｂ3에 대한 항체 및 이의 용도
AU2008218199B2 (en)	2007-02-22	2013-10-31	Genentech, Inc.	Methods for detecting inflammatory bowel disease
SI2132573T1 (sl)	2007-03-02	2014-07-31	Genentech, Inc.	Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
RU2009137582A (ru) *	2007-03-12	2011-04-20	Эсбатек Аг (Ch)	Инженерия и оптимизация одноцепочечных антител на основе последовательности
EP2474556A3 (en)	2007-03-14	2012-10-17	Novartis AG	APCDD1 inhibitors for treating, diagnosing or detecting cancer
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
DK2155248T3 (en)	2007-04-12	2015-09-14	Brigham & Womens Hospital	Targeting abcb5 for cancer therapy
FR2915398B1 (fr) *	2007-04-25	2012-12-28	Lab Francais Du Fractionnement	"ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
WO2008134679A1 (en)	2007-04-30	2008-11-06	Genentech, Inc.	Inhibitors of iap
JP2010526868A (ja)	2007-05-14	2010-08-05	ノビミューンエスアー	改変されたエフェクター機能を有するＦｃ受容体結合ポリペプチド
EP2019101A1 (en) *	2007-07-26	2009-01-28	GPC Biotech AG	Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
RU2473563C2 (ru)	2007-06-07	2013-01-27	Дженентек, Инк.	АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
BRPI0813645A2 (pt)	2007-06-25	2014-12-30	Esbatech Alcon Biomed Res Unit	Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
EP2164961B1 (en) *	2007-06-25	2015-01-07	ESBATech, an Alcon Biomedical Research Unit LLC	Sequence based engineering and optimization of single chain antibodies
KR102055873B1 (ko)	2007-07-09	2019-12-13	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
PE20090943A1 (es)	2007-07-16	2009-08-05	Genentech Inc	Anticuerpos anti-cd79b e inmunoconjugados
EP2176295B1 (en)	2007-07-16	2014-11-19	Genentech, Inc.	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
MX2010000970A (es) *	2007-07-31	2010-03-09	Regeneron Pharma	Anticuerpos humanos contra cd20 humano y metodo para utilizarlos.
ES2453592T3 (es)	2007-08-02	2014-04-08	Novimmune Sa	Anticuerpos anti-RANTES y métodos de uso de los mismos
CN101855346A (zh)	2007-08-24	2010-10-06	肿瘤疗法科学股份有限公司	Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
WO2009028158A1 (en)	2007-08-24	2009-03-05	Oncotherapy Science, Inc.	Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
ES3006441T3 (en)	2007-09-14	2025-03-18	Amgen Inc	Homogeneous antibody populations
KR101680906B1 (ko)	2007-09-26	2016-11-30	추가이 세이야쿠 가부시키가이샤	항체 정상영역 개변체
HUE030134T2 (en)	2007-10-16	2017-04-28	Zymogenetics Inc	Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
ES2533266T5 (es) *	2007-10-30	2018-04-18	Genentech, Inc.	Purificación de anticuerpos mediante cromatografía de intercambio catiónico
KR101867606B1 (ko)	2007-11-07	2018-06-18	제넨테크, 인크.	미생물 질환의 치료를 위한 조성물 및 방법
US8158762B2 (en)	2007-11-08	2012-04-17	Genentech, Inc.	Anti-factor B antibodies and their uses
JP4932940B2 (ja)	2007-11-12	2012-05-16	セラクローンサイエンシーズ，インコーポレイテッド	インフルエンザの治療および診断のための組成物および方法
EP2220247A4 (en)	2007-11-16	2011-10-26	Nuvelo Inc	ANTIBODY AGAINST LRP6
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
RU2010127156A (ru)	2007-12-06	2012-01-20	Дана-Фарбер Кэнсер Инститьют, Инк. (Us)	Антитела против вируса гриппа и их применение
HRP20150279T1 (hr)	2007-12-26	2015-05-08	Xencor, Inc.	Fc inaäśice s promijenjenim vezanjem na fcrn
WO2009086514A1 (en)	2007-12-28	2009-07-09	Dana-Farber Cancer Institute, Inc.	Humanized monoclonal antibodies and methods of use
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2009089295A2 (en)	2008-01-07	2009-07-16	Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Anti-hiv domain antibodies and method of making and using same
ATE548052T1 (de)	2008-01-17	2012-03-15	Philogen Spa	Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
CN101977934B (zh)	2008-01-18	2014-09-17	健泰科生物技术公司	用于靶向k63连接的多聚遍在蛋白的方法和组合物
AR070141A1 (es)	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
KR20100110864A (ko)	2008-01-24	2010-10-13	노보 노르디스크 에이/에스	인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
KR101607346B1 (ko)	2008-01-31	2016-03-29	제넨테크, 인크.	항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
RU2010138612A (ru)	2008-02-20	2012-03-27	Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU)	ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
WO2009111085A1 (en) *	2008-03-07	2009-09-11	Biogen Idec Ma Inc.	Use of cd23 antibodies to treat malignancies in patients with poor prognosis
AU2009223688B2 (en)	2008-03-10	2014-12-11	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
AR072777A1 (es)	2008-03-26	2010-09-22	Cephalon Inc	Formas solidas de clorhidrato de bendamustina
SG10202112838YA (en)	2008-04-09	2021-12-30	Genentech Inc	Novel compositions and methods for the treatment of immune related diseases
RU2531754C2 (ru)	2008-04-11	2014-10-27	ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US	Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
EP2112150B1 (en)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Improved raf inhibitors
EP2112152A1 (en)	2008-04-22	2009-10-28	GPC Biotech AG	Dihydropteridinones as Plk Inhibitors
SG190572A1 (en)	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
WO2009142773A2 (en)	2008-05-22	2009-11-26	Bristol-Myers Squibb Company	Multivalent fibronectin based scaffold domain proteins
CA2726087A1 (en)	2008-06-03	2009-12-10	Tariq Ghayur	Dual variable domain immunoglobulins and uses thereof
TW201006485A (en)	2008-06-03	2010-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CN104592231A (zh)	2008-06-10	2015-05-06	Abbvie公司	新的三环化合物
CA2728829C (en)	2008-06-25	2018-01-02	Esbatech, An Alcon Biomedical Research Unit Llc	Solubility optimization of immunobinders
CN102149825B (zh) *	2008-07-08	2015-07-22	Abbvie公司	前列腺素e2双重可变结构域免疫球蛋白及其用途
ES2442024T3 (es)	2008-07-15	2014-02-07	Academia Sinica	Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
CN102159243B (zh) *	2008-07-21	2015-08-19	免疫医疗公司	用于改良的治疗特征的抗体的结构变体
EP2323679A4 (en)	2008-07-25	2012-08-22	Univ Colorado	CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
JP2011529962A (ja)	2008-08-02	2011-12-15	ジェネンテック，インコーポレイテッド	Ｉａｐのインヒビター
EP2307443B1 (en)	2008-08-07	2013-10-02	Yeda Research And Development Company Ltd.	Affinity purification by cohesin-dockerin interaction
EP4071169A2 (en)	2008-08-25	2022-10-12	Dana Farber Cancer Institute, Inc.	Conserved influenza hemagglutinin epitope and antibodies thereto
AR073295A1 (es)	2008-09-16	2010-10-28	Genentech Inc	Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
CA2735899A1 (en) *	2008-09-25	2010-04-01	Cephalon, Inc.	Liquid formulations of bendamustine
AR073717A1 (es)	2008-10-01	2010-11-24	Genentech Inc	Anticuerpos anti-notch2 de murino y humano, y metodos de uso
WO2010052556A1 (en)	2008-11-06	2010-05-14	Glenmark Pharmaceuticals S.A.	Treatment with anti-alpha2 integrin antibodies
DK2361085T4 (en)	2008-11-22	2018-10-08	Hoffmann La Roche	USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
TWI496582B (zh)	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
MX2011005382A (es)	2008-11-25	2011-07-20	Genentech Inc	Anticuerpos anti-her4 especificos de isoforma.
JP5773315B2 (ja)	2008-11-27	2015-09-02	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	膵癌のバイオマーカーとしてのｃｘｃｌ４ｌ１
EP3255060A1 (en)	2008-12-09	2017-12-13	F. Hoffmann-La Roche AG	Anti-pd-l1 antibodies and their use to enhance t-cell function
KR20110101212A (ko)	2008-12-17	2011-09-15	제넨테크, 인크.	Ｃ형 간염 바이러스 조합 요법
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) *	2009-01-02	2011-06-16	Olav Mella	B-cell depleting agents for the treatment of chronic fatigue syndrome
BRPI1007222A2 (pt)	2009-01-06	2016-02-23	Inserm Inst Nat De La Santé Et De La Rech Médicale	agente de depleção de células b para tratamento de aterosclerose
US8076366B2 (en) *	2009-01-15	2011-12-13	Cephalon, Inc.	Forms of bendamustine free base
KR101722961B1 (ko)	2009-02-11	2017-04-04	알부메딕스 에이/에스	알부민 변이체 및 접합체
US20160095939A1 (en)	2014-10-07	2016-04-07	Immunomedics, Inc.	Neoadjuvant use of antibody-drug conjugates
ES3000111T3 (en)	2009-02-13	2025-02-27	Immunomedics Inc	Intermediates for preparing conjugates with an intracellularly-cleavable linkage
EP2402439B1 (en)	2009-02-27	2018-12-12	Order-made Medical Research Inc.	A method for preparing a hybridoma cell by transplanting breast cancer cells
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
MY152068A (en)	2009-03-20	2014-08-15	Genentech Inc	Bispecific anti-her antibodies
NZ594343A (en)	2009-03-25	2013-10-25	Genentech Inc	Novel anti-alpha5beta1 antibodies and uses thereof
MA33208B1 (fr)	2009-03-25	2012-04-02	Genentech Inc	Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
RU2587621C2 (ru)	2009-04-01	2016-06-20	Дженентек, Инк.	АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2756244A1 (en)	2009-04-02	2010-10-07	Roche Glycart Ag	Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010118243A2 (en)	2009-04-08	2010-10-14	Genentech, Inc.	Use of il-27 antagonists to treat lupus
WO2010121125A1 (en)	2009-04-17	2010-10-21	Wake Forest University Health Sciences	Il-13 receptor binding peptides
US8609101B2 (en)	2009-04-23	2013-12-17	Theraclone Sciences, Inc.	Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
US20110008766A1 (en) *	2009-05-01	2011-01-13	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
CN102458437B (zh)	2009-05-05	2015-06-10	诺维莫尼公司	抗il-17f抗体及其使用方法
EP2432803A2 (en)	2009-05-20	2012-03-28	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
EP2435476A4 (en)	2009-05-27	2013-04-17	Synageva Biopharma Corp	ANTIBODIES OBTAINED FROM BIRDS
MX2011012665A (es)	2009-06-04	2012-03-07	Novartis Ag	Metodos para identificacion de sitios para conjugacion de igg.
US20100316639A1 (en)	2009-06-16	2010-12-16	Genentech, Inc.	Biomarkers for igf-1r inhibitor therapy
WO2010151632A1 (en)	2009-06-25	2010-12-29	Bristol-Myers Squibb Company	Protein purifacation by caprylic acid (octanoic acid ) precipitation
US9290577B2 (en)	2009-07-03	2016-03-22	Avipep Pty Limited	Immuno-conjugates and methods for producing them
US8765431B2 (en)	2009-07-23	2014-07-01	The Regents Of The University Of Michigan	Method for enzymatic production of decarboxylated polyketides and fatty acids
NZ597531A (en)	2009-07-31	2014-05-30	Genentech Inc	Inhibition of tumor metastasis using bv8- or g-csf-antagonists
HRP20200768T4 (hr)	2009-08-11	2025-03-28	F. Hoffmann - La Roche Ag	Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
NZ598131A (en)	2009-08-15	2014-08-29	Genentech Inc	Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CA2772715C (en)	2009-09-02	2019-03-26	Genentech, Inc.	Mutant smoothened and methods of using the same
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2421217C2 (ru) *	2009-09-03	2011-06-20	Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН)	Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2478110B1 (en)	2009-09-16	2016-01-06	Immunomedics, Inc.	Class i anti-cea antibodies and uses thereof
EP2478013B1 (en)	2009-09-16	2018-10-24	F.Hoffmann-La Roche Ag	Coiled coil and/or tether containing protein complexes and uses thereof
EP2480561B1 (en)	2009-09-23	2016-07-13	E. R. Squibb & Sons, L.L.C.	Cation exchange chromatography
EP2482212A4 (en)	2009-09-25	2014-02-26	Sh Nat Eng Res Ct Nanotech Co	METHOD FOR DETECTING HIGH AFFAIR PROTEINS WITH COMPUTER BASED DESIGN
BR112012008833A2 (pt) *	2009-10-15	2015-09-08	Abbott Lab	imunoglobulinas de dominio variavel duplo e usos das mesmas
KR101952453B1 (ko)	2009-10-15	2019-02-26	제넨테크, 인크.	수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
DK2488873T3 (en)	2009-10-16	2015-11-09	Novartis Ag	Biomarkers for pharmacodynamic tumor responses
MX2012002013A (es)	2009-10-19	2012-03-16	Genentech Inc	Moduladores de activador del factor de crecimiento de hepatocitos.
JP5819308B2 (ja)	2009-10-22	2015-11-24	ジェネンテック，インコーポレイテッド	マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
RU2559533C2 (ru)	2009-10-22	2015-08-10	Дженентек, Инк.	Антитела против гепсина и способы их применения
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
SI2493922T1 (sl)	2009-10-26	2017-06-30	F. Hoffmann-La Roche Ag	Postopek za proizvodnjo glikoziliranega imunoglobulina
EP2325185A1 (en)	2009-10-28	2011-05-25	GPC Biotech AG	Plk inhibitor
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2493921B1 (en)	2009-10-30	2018-09-26	Albumedix Ltd	Albumin variants
US20120282276A1 (en)	2009-11-05	2012-11-08	The Regents Of The University Of Michigan	Biomarkers predictive of progression of fibrosis
EP2496601B1 (en)	2009-11-05	2017-06-07	F. Hoffmann-La Roche AG	Methods and composition for secretion of heterologous polypeptides
US9260517B2 (en)	2009-11-17	2016-02-16	Musc Foundation For Research Development	Human monoclonal antibodies to human nucleolin
PH12012500982A1 (en)	2009-11-30	2019-07-10	Genentech Inc	Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
PH12012501000A1 (en)	2009-12-01	2013-02-11	Abbvie Inc	Novel tricyclic compounds
RU2711869C3 (ru)	2009-12-01	2022-02-02	Эббви Инк.	Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
ES2978177T3 (es)	2009-12-02	2024-09-06	Immunomedics Inc	Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
CN102770456B (zh)	2009-12-04	2018-04-06	弗·哈夫曼-拉罗切有限公司	多特异性抗体、抗体类似物、组合物和方法
ES2722300T3 (es)	2009-12-10	2019-08-09	Hoffmann La Roche	Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
WO2011071577A1 (en)	2009-12-11	2011-06-16	Genentech, Inc.	Anti-vegf-c antibodies and methods using same
BR112012013093A2 (pt)	2009-12-21	2017-12-12	Genentech Inc	''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
JP2013514788A (ja)	2009-12-23	2013-05-02	アビペップピーティーワイリミテッド	イムノコンジュゲート及びその作製方法２
EP2516465B1 (en)	2009-12-23	2016-05-18	F.Hoffmann-La Roche Ag	Anti-bv8 antibodies and uses thereof
US9017669B2 (en)	2009-12-28	2015-04-28	Oncotherapy Science, Inc.	Anti-CDH3 antibodies and uses thereof
US20110159588A1 (en)	2009-12-30	2011-06-30	Kui Lin	Methods for Modulating a PDGF-AA Mediated Biological Response
EP2523680A4 (en) *	2010-01-11	2013-06-19	Ct Molecular Med & Immunology	REINFORCED CYTOTOXICITY OF ANTIBODIES TO CD74 AND HLA-DR WITH INTERFERON GAMMA
SG182408A1 (en)	2010-01-11	2012-08-30	Alexion Pharma Inc	Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
JP2013517464A (ja)	2010-01-15	2013-05-16	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	皮膚ｔ細胞リンパ腫の診断及び処置のための方法
WO2011097527A2 (en)	2010-02-04	2011-08-11	Xencor, Inc.	Immunoprotection of therapeutic moieties using enhanced fc regions
US9175086B2 (en) *	2010-02-10	2015-11-03	Immunogen, Inc.	CD20 antibodies and uses thereof
US20120296403A1 (en)	2010-02-10	2012-11-22	Novartis Ag	Methods and compounds for muscle growth
KR20130009760A (ko) *	2010-02-10	2013-01-23	이뮤노젠 아이엔씨	Ｃｄ２０ 항체 및 이의 용도
KR20130036192A (ko)	2010-02-11	2013-04-11	알렉시온 파마슈티칼스, 인코포레이티드	항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
US9556249B2 (en)	2010-02-18	2017-01-31	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
JP2013520426A (ja)	2010-02-18	2013-06-06	ブリストル−マイヤーズスクイブカンパニー	Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質
MA34057B1 (fr)	2010-02-23	2013-03-05	Genentech Inc	Compositions et methodes pour le diagnostic et le traitement d'une tumeur
TWI619509B (zh)	2010-02-23	2018-04-01	建南德克公司	治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合
CA2790866C (en)	2010-02-23	2019-02-12	Sanofi	Anti-alpha2 integrin antibodies and their uses
US9169323B2 (en)	2010-03-05	2015-10-27	Hoffmann-La Roche Inc.	Antibodies against human CSF-1R
JP5989547B2 (ja)	2010-03-05	2016-09-07	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	ヒトｃｓｆ−１ｒに対する抗体及びその使用
AR080795A1 (es)	2010-03-24	2012-05-09	Genentech Inc	Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
JP2013528357A (ja)	2010-03-29	2013-07-11	ザイムワークス，インコーポレイテッド	強化又は抑制されたエフェクター機能を有する抗体
HUE049849T2 (hu)	2010-03-31	2020-10-28	Boehringer Ingelheim Int	Anti-CD40 antitestek
ES2993140T3 (en)	2010-04-02	2024-12-23	Amunix Pharmaceuticals Inc	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP2374816B1 (en)	2010-04-07	2016-09-28	Agency For Science, Technology And Research	Binding molecules against Chikungunya virus and uses thereof
EP2556087A1 (en)	2010-04-09	2013-02-13	Novozymes Biopharma DK A/S	Albumin derivatives and variants
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
EP2558491B1 (en)	2010-04-13	2018-07-04	Bristol-Myers Squibb Company	Fibronectin based scaffold domain proteins that bind pcsk9
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
KR101860963B1 (ko)	2010-04-23	2018-05-24	제넨테크, 인크.	이종다량체 단백질의 생산
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
TW201138808A (en)	2010-05-03	2011-11-16	Bristol Myers Squibb Co	Serum albumin binding molecules
EP2566512A1 (en)	2010-05-04	2013-03-13	Merrimack Pharmaceuticals, Inc.	Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en)	2010-05-04	2011-11-10	Dyax Corp.	Antibodies against epidermal growth factor receptor (egfr)
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
KR101976853B1 (ko)	2010-05-25	2019-05-09	제넨테크, 인크.	폴리펩티드의 정제 방법
JP6023703B2 (ja)	2010-05-26	2016-11-09	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
EP2576622A4 (en)	2010-06-01	2013-11-27	Univ Monash	ON THE UNPROCESSED RECEPTOR TYROSINE KINASE C-MET TARGETED ANTIBODIES
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
AU2011261396B2 (en)	2010-06-02	2015-11-05	Dana-Farber Cancer Institute, Inc.	Humanized monoclonal antibodies and methods of use
NZ701208A (en)	2010-06-03	2016-05-27	Genentech Inc	Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
CA2799540A1 (en)	2010-06-08	2011-12-15	Genentech, Inc.	Cysteine engineered antibodies and conjugates
RU2577986C2 (ru)	2010-06-18	2016-03-20	Дженентек, Инк.	Антитела против axl и способы их применения
EP3323830B1 (en)	2010-06-19	2023-08-23	Memorial Sloan-Kettering Cancer Center	Anti-gd2 antibodies
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
WO2012010582A1 (en)	2010-07-21	2012-01-26	Roche Glycart Ag	Anti-cxcr5 antibodies and methods of use
EP2596026B1 (en)	2010-07-23	2020-04-08	Trustees of Boston University	Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
KR20130045914A (ko)	2010-08-03	2013-05-06	에프. 호프만-라 로슈 아게	만성 림프구성 백혈병(cll) 생체지표
EP3252072A3 (en)	2010-08-03	2018-03-14	AbbVie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CA2807664A1 (en)	2010-08-12	2012-02-16	Theraclone Sciences, Inc.	Anti-hemagglutinin antibody compositions and methods of use thereof
EP2603529A1 (en)	2010-08-13	2013-06-19	Roche Glycart AG	Anti-tenascin-c a2 antibodies and methods of use
CA2806021C (en)	2010-08-13	2019-05-21	Roche Glycart Ag	Anti-fap antibodies and methods of use
CA2808185A1 (en)	2010-08-13	2012-02-16	Genentech, Inc.	Antibodies to il-1.beta. and il-18, for treatment of disease
CN103068846B9 (zh)	2010-08-24	2016-09-28	弗·哈夫曼-拉罗切有限公司	包含二硫键稳定性Fv片段的双特异性抗体
US8598408B2 (en)	2010-08-25	2013-12-03	Ordermade Medical Research Inc.	Method of producing an antibody using a cancer cell
JP2013539364A (ja)	2010-08-26	2013-10-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリンおよびその使用
SG10201506782XA (en)	2010-08-27	2015-10-29	Stem Centrx Inc	Notum protein modulators and methods of use
MX2013002084A (es)	2010-08-31	2013-05-09	Genentech Inc	Biomarcadores y metodos de tratamiento.
PT3556396T (pt)	2010-08-31	2022-07-04	Scripps Research Inst	Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
WO2012030512A1 (en)	2010-09-03	2012-03-08	Percivia Llc.	Flow-through protein purification process
AU2011295715B9 (en)	2010-09-03	2017-02-23	Abbvie Stemcentrx Llc	Novel modulators and methods of use
MX347954B (es)	2010-09-29	2017-05-19	Agensys Inc	Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
EP2625189B1 (en)	2010-10-01	2018-06-27	ModernaTX, Inc.	Engineered nucleic acids and methods of use thereof
DK2625197T3 (en)	2010-10-05	2016-10-03	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
CA2814030C (en)	2010-10-08	2019-04-30	Shanghai Kexin Biotech Co., Ltd.	Diagnostic and therapeutic uses of moesin fragments
EP2624851B1 (en)	2010-10-08	2016-11-30	Shanghai Kexin Biotech Co., Ltd	Moesin fragments and uses thereof
WO2012045274A1 (en)	2010-10-08	2012-04-12	Shanghai Kexin Biotech Co., Ltd.	Moesin modulators and uses thereof
US9354241B2 (en)	2010-10-08	2016-05-31	Shanghai Kexin Biotech Co., Ltd.	Moesin fragments associated with aplastic anemia
CA2814029C (en)	2010-10-08	2017-05-09	Shanghai Kexin Biotech Co., Ltd.	Moesin fragments associated with immune thrombocytopenia
MX2019000046A (es)	2010-11-04	2023-10-05	Boehringer Ingelheim Int	Anticuerpos anti-il-23.
KR20190120439A (ko)	2010-11-08	2019-10-23	제넨테크, 인크.	피하 투여용 항―ｉｌ―6 수용체 항체
WO2012064836A1 (en)	2010-11-10	2012-05-18	Genentech, Inc.	Methods and compositions for neural disease immunotherapy
EP2640359A4 (en)	2010-11-18	2015-11-04	Gen Hospital Corp	NOVEL COMPOSITIONS AND USES OF HYPOTENSE AGENTS IN THE TREATMENT OF CANCER
NZ611428A (en)	2010-12-08	2015-07-31	Stemcentrx Inc	Novel modulators and methods of use
RU2578468C2 (ru)	2010-12-16	2016-03-27	Дженентек, Инк.	Способы диагностики и лечения, связанные с ингибированием th2
BR112013014527A2 (pt)	2010-12-20	2017-03-07	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
CN103380143B (zh)	2010-12-22	2016-01-06	百时美施贵宝公司	结合il-23的基于纤连蛋白的支架结构域蛋白质
CN103261230A (zh)	2010-12-22	2013-08-21	霍夫曼-拉罗奇有限公司	抗pcsk9抗体及使用方法
US9505826B2 (en)	2010-12-22	2016-11-29	Teva Pharmaceuticals Australia Pty Ltd	Modified antibody with improved half-life
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
EP3604339B1 (en)	2011-01-14	2021-03-10	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
RU2018108836A (ru)	2011-02-04	2019-03-14	Дженентек, Инк.	ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2012112489A2 (en)	2011-02-14	2012-08-23	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
AU2012225246B2 (en)	2011-03-10	2016-01-21	Omeros Corporation	Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
EP2683735A1 (en)	2011-03-10	2014-01-15	HCO Antibody, Inc.	Bispecific three-chain antibody-like molecules
BR112013023576A2 (pt)	2011-03-15	2016-12-06	Theraclone Sciences Inc	composições e métodos para a terapia e diagnóstico de influenza
TWI743461B (zh)	2011-03-28	2021-10-21	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2692268T5 (en)	2011-03-29	2025-02-26	Roche Glycart Ag	Antibody fc variants
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
CA2828890A1 (en)	2011-04-07	2012-10-11	Genentech, Inc.	Anti-fgfr4 antibodies and methods of use
EP3415528B1 (en)	2011-04-13	2021-05-26	Bristol-Myers Squibb Company	Fc fusion proteins comprising novel linkers or arrangements
RU2013150331A (ru)	2011-04-20	2015-05-27	Рош Гликарт Аг	СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
JP6038121B2 (ja)	2011-04-21	2016-12-07	ガーバンインスティテュートオブメディカルリサーチ	修飾された可変ドメイン分子及びその製造及び使用の方法ｂ
US8852592B2 (en)	2011-05-10	2014-10-07	Biocare Medical, Llc	Systems and methods for anti-PAX8 antibodies
WO2012158818A2 (en)	2011-05-16	2012-11-22	Fabion Pharmaceuticals, Inc.	Multi-specific fab fusion proteins and methods of use
EA030462B1 (ru)	2011-05-16	2018-08-31	Дженентек, Инк.	Агонисты fgfr1 и способы их применения
US20140107321A1 (en)	2011-05-26	2014-04-17	Dr. Reddy's Laboratories Limited	Purification of antibodies
US8691231B2 (en)	2011-06-03	2014-04-08	Merrimack Pharmaceuticals, Inc.	Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
CN103732623B (zh)	2011-06-03	2017-09-29	佐马技术有限公司	对TGF‑β具有特异性的抗体
DK3424953T3 (en)	2011-06-06	2020-11-02	Novo Nordisk As	Terapeutiske antistoffer
RU2011122942A (ru)	2011-06-08	2012-12-20	Общество С Ограниченной Ответственностью "Асинэкс Медхим"	Новые ингибиторы киназ
EP2537933A1 (en)	2011-06-24	2012-12-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2724157B1 (en)	2011-06-27	2017-03-08	Valneva	Method for screening cells
AR086823A1 (es)	2011-06-30	2014-01-22	Genentech Inc	Formulaciones de anticuerpo anti-c-met, metodos
JP2013040160A (ja)	2011-07-01	2013-02-28	Genentech Inc	自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
CN103827143A (zh) *	2011-07-06	2014-05-28	莫弗系统股份公司	抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013012733A1 (en)	2011-07-15	2013-01-24	Biogen Idec Ma Inc.	Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US20130022551A1 (en)	2011-07-22	2013-01-24	Trustees Of Boston University	DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
AR087364A1 (es) *	2011-07-29	2014-03-19	Pf Medicament	Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
WO2013025446A2 (en)	2011-08-12	2013-02-21	Omeros Corporation	Anti-fzd10 monoclonal antibodies and methods for their use
KR20140068877A (ko)	2011-08-17	2014-06-09	제넨테크, 인크.	불응성 종양에서의 혈관신생의 억제
MX2014001766A (es)	2011-08-17	2014-05-01	Genentech Inc	Anticuerpos de neuregulina y sus usos.
WO2013026839A1 (en)	2011-08-23	2013-02-28	Roche Glycart Ag	Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
JP6060162B2 (ja)	2011-08-23	2017-01-11	ロシュグリクアートアーゲー	２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
RU2014109038A (ru)	2011-08-23	2015-09-27	Рош Гликарт Аг	Антитела к хондроитинсульфат протеогликану меланомы
US8822651B2 (en)	2011-08-30	2014-09-02	Theraclone Sciences, Inc.	Human rhinovirus (HRV) antibodies
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
PH12014500544B1 (en)	2011-09-09	2019-03-13	Dept Of Medical Sciences Dmsc	Dengue-virus serotype neutralizing antibodies
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
WO2013040433A1 (en)	2011-09-15	2013-03-21	Genentech, Inc.	Methods of promoting differentiation
SG11201400724SA (en)	2011-09-19	2014-04-28	Genentech Inc	Combination treatments comprising c-met antagonists and b-raf antagonists
JP6041882B2 (ja)	2011-09-23	2016-12-14	ロシュグリクアートアーゲー	二重特異性抗ｅｇｆｒ／抗ｉｇｆ−１ｒ抗体
EP2748198A2 (en)	2011-09-27	2014-07-02	The United States of America, as represented by The Secretary, Department of Health and Human Services	Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
DE19216461T1 (de)	2011-10-03	2021-10-07	Modernatx, Inc.	Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US9663573B2 (en)	2011-10-05	2017-05-30	Genentech, Inc.	Methods of treating liver conditions using Notch2 antagonists
RU2654567C2 (ru)	2011-10-11	2018-05-21	Дженентек, Инк.	Улучшенная сборка биспецифических антител
BR112014008862A2 (pt)	2011-10-14	2018-08-07	Genentech Inc	anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
US9358250B2 (en)	2011-10-15	2016-06-07	Genentech, Inc.	Methods of using SCD1 antagonists
US20140288279A1 (en)	2011-10-21	2014-09-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
AU2012328819B2 (en)	2011-10-26	2017-08-03	Elanco Tiergesundheit Ag	Monoclonal antibodies and methods of use
EP3559049B1 (en)	2011-10-28	2025-06-11	Teva Pharmaceuticals Australia Pty Ltd	Polypeptide constructs and uses thereof
MX2014004991A (es)	2011-10-28	2014-05-22	Genentech Inc	Combinaciones terapeuticas y metodos para tratar el melanoma.
JP2015504038A (ja)	2011-10-31	2015-02-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	低減した免疫原性を有するフィブロネクチン結合ドメイン
HUE035685T2 (en)	2011-11-02	2018-05-28	Hoffmann La Roche	Overload and elute chromatography
SI3536710T1 (sl)	2011-11-16	2026-04-30	Boehringer Ingelheim International Gmbh	Protitelesa proti IL-36R
EP2780364A2 (en)	2011-11-18	2014-09-24	Eleven Biotherapeutics, Inc.	Proteins with improved half-life and other properties
SG11201402485UA (en)	2011-11-21	2014-06-27	Genentech Inc	Purification of anti-c-met antibodies
ES2651521T3 (es)	2011-12-01	2018-01-26	Innovent Biologics, Inc.	Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
US9757458B2 (en)	2011-12-05	2017-09-12	Immunomedics, Inc.	Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en)	2011-12-05	2013-06-13	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
RU2658603C2 (ru)	2011-12-15	2018-06-21	Ф.Хоффманн-Ля Рош Аг	Антитела против человеческого csf-1r и их применения
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
US20130195851A1 (en)	2011-12-23	2013-08-01	Genentech, Inc.	Articles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CA2863224A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
JP2015509091A (ja)	2012-01-09	2015-03-26	ザスクリプスリサーチインスティテュート	ヒト化抗体
JP2015506944A (ja)	2012-01-18	2015-03-05	ジェネンテック，インコーポレイテッド	Ｆｇｆ１９修飾薬を使用する方法
US9200072B2 (en)	2012-01-18	2015-12-01	Genentech Inc.	Anti-LRP5 antibodies and methods of use
KR20140119777A (ko)	2012-01-31	2014-10-10	제넨테크, 인크.	항-ig-e m1'' 항체 및 그의 사용 방법
US9567642B2 (en)	2012-02-02	2017-02-14	Massachusetts Institute Of Technology	Methods and products related to targeted cancer therapy
KR102100388B1 (ko)	2012-02-06	2020-04-13	인히브릭스, 인크.	Cd47 항체 및 그 사용 방법
CA2861124A1 (en)	2012-02-10	2013-08-15	Genentech, Inc.	Single-chain antibodies and other heteromultimers
KR102148303B1 (ko)	2012-02-11	2020-08-26	제넨테크, 인크.	R-스폰딘 전위 및 그의 사용 방법
MX360352B (es)	2012-02-15	2018-10-30	Hoffmann La Roche	Cromatografia de afinidad basada en receptores fc.
BR112014020826A8 (pt)	2012-02-24	2017-09-19	Stem Centrx Inc	Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
EP3539985A1 (en)	2012-02-24	2019-09-18	AbbVie Stemcentrx LLC	Anti sez6 antibodies and methods of use
DK2825556T3 (en)	2012-03-16	2018-04-16	Albumedix As	albumin Variants
HUE037613T2 (hu)	2012-03-29	2018-09-28	Novimmune Sa	Anti-TLR4 antitestek és azok felhasználása
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10316103B1 (en)	2012-03-30	2019-06-11	Biocare Medical, Llc	Systems and methods for anti-Uroplakin III antibodies
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CN110078827A (zh)	2012-04-27	2019-08-02	西托姆克斯治疗公司	结合表皮生长因子受体的可活化的抗体其使用方法
US9056910B2 (en)	2012-05-01	2015-06-16	Genentech, Inc.	Anti-PMEL17 antibodies and immunoconjugates
JP6473079B2 (ja)	2012-05-02	2019-02-20	ライフテクノロジーズコーポレーション	高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
PL3326649T3 (pl)	2012-05-03	2022-04-25	Boehringer Ingelheim International Gmbh	Przeciwciała anty-il-23p19
EP3511343A1 (en)	2012-05-04	2019-07-17	Dana Farber Cancer Institute, Inc.	Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
EP2861624A1 (en)	2012-06-15	2015-04-22	F. Hoffmann-La Roche AG	Anti-pcsk9 antibodies, formulations, dosing, and methods of use
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko)	2012-06-27	2015-03-20	에프. 호프만-라 로슈 아게	표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
WO2014001326A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
RU2684595C2 (ru)	2012-07-04	2019-04-09	Ф.Хоффманн-Ля Рош Аг	Ковалентно связанные конъюгаты антиген-антитело
DK2869837T3 (en)	2012-07-04	2016-09-26	Hoffmann La Roche	Anti-theophylline antibodies and methods of use
EP2870180B1 (en)	2012-07-04	2024-08-28	F. Hoffmann-La Roche AG	Anti-biotin antibodies and methods of use
IN2014DN10652A (ro)	2012-07-09	2015-09-11	Genentech Inc
AR091703A1 (es)	2012-07-09	2015-02-25	Genentech Inc	Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22
CN104411337A (zh)	2012-07-09	2015-03-11	基因泰克公司	包含抗cd79b抗体的免疫偶联物
CN104428007B (zh)	2012-07-09	2018-03-16	基因泰克公司	包含抗cd22抗体的免疫缀合物
SG11201408538PA (en)	2012-07-13	2015-02-27	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EP2879710B1 (en)	2012-08-03	2019-11-13	Dana-Farber Cancer Institute, Inc.	Medical uses of agents that modulate immune cell activation and corresponding screening methods
CN104379169A (zh)	2012-08-14	2015-02-25	Ibc药品公司	用于治疗疾病的t-细胞重定向双特异性抗体
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
TWI606063B (zh)	2012-08-23	2017-11-21	艾澤西公司	結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
ES2984405T3 (es)	2012-09-13	2024-10-29	Bristol Myers Squibb Co	Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
JP6352924B2 (ja)	2012-09-19	2018-07-04	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	ダイナミックｂｈ３プロファイリング
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2900265B1 (en)	2012-09-27	2018-05-30	Biocare Medical, LLC	Anti-uroplakin ii antibodies systems and methods
BR112015007672A2 (pt)	2012-10-04	2017-08-08	Dana Farber Cancer Inst Inc	anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RU2015117393A (ru)	2012-10-08	2016-12-10	Роше Гликарт Аг	Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
TW202037609A (zh)	2012-11-01	2020-10-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
CN110669136A (zh)	2012-11-05	2020-01-10	全药工业株式会社	抗体或抗体组合物的制备方法
MA38165A1 (fr)	2012-11-08	2018-07-31	Hoffmann La Roche	Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
MX2015005363A (es)	2012-11-08	2015-11-06	Novozymes Biopharma Dk As	Variantes de albumina.
CN104968367B (zh)	2012-11-13	2018-04-13	弗·哈夫曼-拉罗切有限公司	抗血凝素抗体和使用方法
CN105051528A (zh)	2012-11-15	2015-11-11	弗·哈夫曼-拉罗切有限公司	离子强度介导的pH梯度离子交换色谱
DK3199552T3 (da)	2012-11-20	2020-03-30	Sanofi Sa	Anti-ceacam5-antistoffer og anvendelser heraf
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
DK3725807T3 (da)	2012-12-03	2026-01-12	Novimmune Sa	Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
US9492566B2 (en)	2012-12-13	2016-11-15	Immunomedics, Inc.	Antibody-drug conjugates and uses thereof
US10137196B2 (en)	2012-12-13	2018-11-27	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10744129B2 (en)	2012-12-13	2020-08-18	Immunomedics, Inc.	Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
CN107753954A (zh)	2012-12-13	2018-03-06	免疫医疗公司	功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US20240139324A1 (en)	2012-12-13	2024-05-02	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US12310958B2 (en)	2012-12-13	2025-05-27	Immunomedics, Inc.	Antibody-drug conjugates and uses thereof
WO2017004144A1 (en)	2015-07-01	2017-01-05	Immunomedics, Inc.	Antibody-sn-38 immunoconjugates with a cl2a linker
US10206918B2 (en)	2012-12-13	2019-02-19	Immunomedics, Inc.	Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9931417B2 (en)	2012-12-13	2018-04-03	Immunomedics, Inc.	Antibody-SN-38 immunoconjugates with a CL2A linker
WO2015012904A2 (en)	2012-12-13	2015-01-29	Immunomedics, Inc.	Antibody-sn-38 immunoconjugates with a cl2a linker
US10413539B2 (en)	2012-12-13	2019-09-17	Immunomedics, Inc.	Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10429390B2 (en)	2012-12-18	2019-10-01	Biocare Medical, Llc	Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
HK1210713A1 (en)	2012-12-27	2016-05-06	Sanofi	Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
WO2014116749A1 (en)	2013-01-23	2014-07-31	Genentech, Inc.	Anti-hcv antibodies and methods of using thereof
EP2951206A2 (en)	2013-02-01	2015-12-09	Bristol-Myers Squibb Company	Fibronectin based scaffold proteins
NZ710695A (en)	2013-02-06	2020-05-29	Inhibrx Inc	Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
ES2731681T3 (es)	2013-02-22	2019-11-18	Abbvie Stemcentrx Llc	Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
US20140242083A1 (en)	2013-02-26	2014-08-28	Roche Glycart Ag	Anti-mcsp antibodies
DK2962113T3 (da)	2013-02-28	2019-07-01	Biocare Medical Llc	Systemer og fremgangsmåder med anti-p40-antistoffer
MX2015011428A (es)	2013-03-06	2016-02-03	Genentech Inc	Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
AR095398A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida
CN110538322A (zh)	2013-03-13	2019-12-06	豪夫迈·罗氏有限公司	抗体配制剂
RU2707550C2 (ru)	2013-03-13	2019-11-27	Дженентек, Инк.	Составы со сниженным окислением
MX369671B (es)	2013-03-13	2019-11-15	Genentech Inc	Formulaciones con oxidacion reducida.
EP2968587A2 (en)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
AR095399A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida, método
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
JP2016516046A (ja)	2013-03-14	2016-06-02	ジェネンテック，インコーポレイテッド	がんの治療方法及びがん薬物耐性を阻止する方法
JP6436965B2 (ja)	2013-03-14	2018-12-12	ジェネンテック，インコーポレイテッド	抗ｂ７−ｈ４抗体及びイムノコンジュゲート
SG11201507427QA (en)	2013-03-15	2015-10-29	Genentech Inc	Compositions and methods for diagnosis and treatment of hepatic cancers
CA2905123A1 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
KR20150131177A (ko)	2013-03-15	2015-11-24	제넨테크, 인크.	항-CRTh2 항체 및 그의 용도
JP2016513478A (ja)	2013-03-15	2016-05-16	ジェネンテック，インコーポレイテッド	細胞培養培地及び抗体を産生する方法
MX367668B (es)	2013-03-15	2019-08-30	Dana Farber Cancer Inst Inc	Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
BR112015023120A2 (pt)	2013-03-15	2017-11-21	Genentech Inc	método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2014143739A2 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
AU2014233393B2 (en)	2013-03-15	2020-05-28	Genentech, Inc.	Cell culture compositions with antioxidants and methods for polypeptide production
RU2680267C2 (ru)	2013-03-15	2019-02-19	Мемориал Слоан Кеттеринг Кэнсер Сентер	Высокоаффинные антитела к gd2
WO2014144280A2 (en)	2013-03-15	2014-09-18	Abbvie Inc.	DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2014150877A2 (en)	2013-03-15	2014-09-25	Ac Immune S.A.	Anti-tau antibodies and methods of use
WO2014144466A1 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
CA2908380A1 (en)	2013-04-09	2014-10-16	Boston Biomedical, Inc.	Methods for treating cancer
AR095882A1 (es)	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2014177459A2 (en)	2013-04-29	2014-11-06	F. Hoffmann-La Roche Ag	Fc-receptor binding modified asymmetric antibodies and methods of use
WO2014179657A1 (en)	2013-05-03	2014-11-06	Eleven Biotherapeutics, Inc.	Albumin variants binding to fcrn
EP3594240B1 (en)	2013-05-20	2023-12-06	F. Hoffmann-La Roche AG	Anti-transferrin receptor antibodies and methods of use
KR20160018579A (ko)	2013-06-04	2016-02-17	싸이톰스 테라퓨틱스, 인크.	활성화가능 항체를 접합하기 위한 조성물 및 방법
EP3013365B1 (en)	2013-06-26	2019-06-05	Academia Sinica	Rm2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
AU2014287044B2 (en)	2013-07-12	2020-02-06	Genentech, Inc.	Elucidation of ion exchange chromatography input optimization
WO2015017146A2 (en)	2013-07-18	2015-02-05	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CA2918370A1 (en)	2013-07-18	2015-01-22	Fabrus, Inc.	Humanized antibodies with ultralong complementarity determining regions
US11253606B2 (en)	2013-07-23	2022-02-22	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN105722859B (zh)	2013-07-25	2021-05-07	西托姆克斯治疗公司	多特异性抗体、多特异性可活化抗体及其使用方法
PL3027656T3 (pl) *	2013-07-30	2019-10-31	Sbi Biotech Co Ltd	Lek zawierający przeciwciało anty-fosfolipazowe D4
WO2015017552A1 (en)	2013-08-01	2015-02-05	Agensys, Inc.	Antibody drug conjugates (adc) that bind to cd37 proteins
SG11201601044XA (en)	2013-08-12	2016-03-30	Genentech Inc	Compositions and method for treating complement-associated conditions
US10077304B2 (en)	2013-08-14	2018-09-18	The Governing Council Of The University Of Toronto	Antibodies against frizzled receptor
CN105792836A (zh)	2013-08-28	2016-07-20	施特姆森特克斯股份有限公司	新型sez6调节剂以及应用方法
SG11201601424PA (en)	2013-08-28	2016-03-30	Stemcentrx Inc	Site-specific antibody conjugation methods and compositions
US20150093800A1 (en)	2013-09-05	2015-04-02	Genentech, Inc.	Method for chromatography reuse
JP6486368B2 (ja)	2013-09-06	2019-03-20	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN120904322A (zh)	2013-09-13	2025-11-07	豪夫迈·罗氏有限公司	包含纯化的重组多肽的方法和组合物
RU2016107435A (ru)	2013-09-13	2017-10-18	Дженентек, Инк.	Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
JP2016537399A (ja)	2013-09-17	2016-12-01	ジェネンテック，インコーポレイテッド	抗ｌｇｒ５抗体を使用する方法
BR112015032713B1 (pt)	2013-09-17	2023-03-21	Obi Pharma, Inc	Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
AU2014323526B2 (en)	2013-09-19	2020-07-23	Dana-Farber Cancer Institute, Inc.	Methods of BH3 profiling
NZ718283A (en)	2013-09-25	2022-05-27	Cytomx Therapeutics Inc	Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
MY175472A (en)	2013-09-27	2020-06-29	Genentech Inc	Anti-pdl1 antibody formulations
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
US9816997B2 (en)	2013-10-03	2017-11-14	Biocare Medical, Llc	Anti-SOX10 antibody systems and methods
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
MX384984B (es)	2013-10-10	2025-03-14	Beth Israel Deaconess Medical Ct Inc	Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
BR112016008477A2 (pt)	2013-10-18	2017-10-03	Genentech Inc	Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
WO2015066279A2 (en)	2013-10-30	2015-05-07	Cytomx Therapeutics, Inc.	Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
JP2016538275A (ja)	2013-11-04	2016-12-08	グレンマークファーマシューティカルズ，エセ．アー．	Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
JP2016540826A (ja)	2013-11-04	2016-12-28	ファイザー・インク	抗ｅｆｎａ４抗体−薬物コンジュゲート
RU2016122041A (ru)	2013-11-06	2017-12-11	ЭББВИ СТЕМСЕНТРКС ЭлЭлСи	Новые анти-клаудин антитела и способы их применения
WO2015068781A1 (ja)	2013-11-06	2015-05-14	国立大学法人大阪大学	インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
WO2015070210A1 (en)	2013-11-11	2015-05-14	Wake Forest University Health Sciences	Epha3 and multi-valent targeting of tumors
NZ720769A (en)	2013-12-09	2022-10-28	Allakos Inc	Anti-siglec-8 antibodies and methods of use thereof
WO2015089283A1 (en)	2013-12-11	2015-06-18	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
SG11201604784XA (en)	2013-12-13	2016-07-28	Genentech Inc	Anti-cd33 antibodies and immunoconjugates
WO2015095423A2 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
AU2014364593A1 (en)	2013-12-17	2016-07-07	Genentech, Inc.	Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
JP2017507900A (ja)	2013-12-17	2017-03-23	ジェネンテック，インコーポレイテッド	Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
TWI670283B (zh)	2013-12-23	2019-09-01	美商建南德克公司	抗體及使用方法
EP3089758B1 (en)	2014-01-03	2021-01-27	F.Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CN105899540B (zh)	2014-01-03	2020-02-07	豪夫迈·罗氏有限公司	双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用
BR112016014945A2 (pt)	2014-01-03	2018-01-23	F. Hoffmann-La Roche Ag	conjugado, formulação farmacêutica e uso
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en)	2015-01-16	2016-07-21	Academia Sinica	Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en)	2014-01-16	2016-07-07	Academia Sinica	Compositions and methods for treatment and detection of cancers
EP3096797A1 (en)	2014-01-24	2016-11-30	F. Hoffmann-La Roche AG	Methods of using anti-steap1 antibodies and immunoconjugates
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
EA033604B1 (ru)	2014-01-31	2019-11-08	Boehringer Ingelheim Int	Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
US9562073B2 (en)	2014-01-31	2017-02-07	Cytomx Therapeutics, Inc.	Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
ES2694857T3 (es)	2014-02-04	2018-12-27	Genentech, Inc.	Smoothened mutante y métodos de uso de la misma
EA201691610A8 (ru)	2014-02-12	2018-05-31	Дженентек, Инк.	Анти-jagged1 антитела и способы применения
CA2939941A1 (en)	2014-02-21	2015-08-27	Abbvie Stemcentrx Llc	Anti-dll3 antibodies and drug conjugates for use in melanoma
UA117608C2 (uk)	2014-02-21	2018-08-27	Дженентек, Інк.	Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
JP6447933B2 (ja)	2014-02-21	2019-01-09	アイビーシーファーマスーティカルズ，インコーポレイテッド	Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en)	2014-02-25	2015-09-03	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
DK3110446T3 (da)	2014-02-28	2022-02-28	Allakos Inc	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
PL3116891T3 (pl)	2014-03-10	2020-07-27	Richter Gedeon Nyrt.	Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
US9738702B2 (en)	2014-03-14	2017-08-22	Janssen Biotech, Inc.	Antibodies with improved half-life in ferrets
AU2015229035B2 (en)	2014-03-14	2021-08-05	Genentech, Inc.	Methods and compositions for secretion of heterologous polypeptides
EP4043489A1 (en)	2014-03-19	2022-08-17	Dana-Farber Cancer Institute, Inc.	Immunogenetic restriction on elicitation of antibodies
TWI701042B (zh)	2014-03-19	2020-08-11	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
CA2943228C (en)	2014-03-20	2023-03-14	Bristol-Myers Squibb Company	Stabilized fibronectin based scaffold molecules
ES2736127T3 (es)	2014-03-20	2019-12-26	Bristol Myers Squibb Co	Dominios de tipo III de fibronectina de unión a seroalbúmina
CN106103478B (zh)	2014-03-21	2020-04-03	豪夫迈·罗氏有限公司	抗体体内半寿期的体外预测
RU2016141385A (ru)	2014-03-24	2018-04-28	Дженентек, Инк.	Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
CN103897059B (zh) *	2014-03-27	2016-03-23	中国人民解放军军事医学科学院生物工程研究所	抗cd20抗原的抗体l5h7及其应用
CN106415244B (zh)	2014-03-27	2020-04-24	中央研究院	反应性标记化合物及其用途
SG11201607969XA (en)	2014-03-31	2016-10-28	Genentech Inc	Anti-ox40 antibodies and methods of use
KR20160146747A (ko)	2014-03-31	2016-12-21	제넨테크, 인크.	항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
KR20160145813A (ko)	2014-04-25	2016-12-20	다나-파버 캔서 인스티튜트 인크.	중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
RU2708075C2 (ru)	2014-04-30	2019-12-04	Пфайзер Инк.	Конъюгаты анти-ртк7 антитело-лекарственное средство
BR122021009041B1 (pt)	2014-05-06	2022-11-29	Genentech, Inc	Métodos para a preparação de uma proteína heteromultimérica
WO2015179658A2 (en)	2014-05-22	2015-11-26	Genentech, Inc.	Anti-gpc3 antibodies and immunoconjugates
RU2016144405A (ru)	2014-05-23	2018-06-26	Дженентек, Инк.	MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950415A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
CN106661099A (zh)	2014-05-27	2017-05-10	中央研究院	抗her2醣抗体及其用途
JP7093612B2 (ja)	2014-05-27	2022-06-30	アカデミアシニカ	Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
WO2015184001A1 (en)	2014-05-28	2015-12-03	Academia Sinica	Anti-tnf-alpha glycoantibodies and uses thereof
EP3613433B1 (en)	2014-05-30	2022-01-05	Shanghai Henlius Biotech, Inc.	Anti-epidermal growth factor receptor (egfr) antibodies
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
TWI695011B (zh)	2014-06-18	2020-06-01	美商梅爾莎納醫療公司	抗ｈｅｒ２表位之單株抗體及其使用之方法
EP3160504B1 (en)	2014-06-24	2020-09-16	Immunomedics, Inc.	Anti-histone therapy for vascular necrosis in severe glomerulonephritis
BR112016029935A2 (pt)	2014-06-26	2017-10-31	Hoffmann La Roche	?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
RU2715038C2 (ru)	2014-07-11	2020-02-21	Дженентек, Инк.	Антитела анти-pd-l1 и способы их диагностического применения
CN106488775A (zh)	2014-07-11	2017-03-08	基因泰克公司	Notch途径抑制
EP3708679A1 (en)	2014-07-24	2020-09-16	Boehringer Ingelheim International GmbH	Biomarkers useful in the treatment of il-23a related diseases
CA2955947A1 (en)	2014-07-25	2016-01-28	Cytomx Therapeutics, Inc.	Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US20170226209A1 (en)	2014-08-01	2017-08-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	An anti-cd45rc antibody for use as drug
DK4074735T3 (da)	2014-08-28	2025-07-14	Bioatla Inc	Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
TWI751102B (zh)	2014-08-28	2022-01-01	美商奇諾治療有限公司	對ｃｄ１９具專一性之抗體及嵌合抗原受體
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
WO2016040724A1 (en)	2014-09-12	2016-03-17	Genentech, Inc.	Anti-b7-h4 antibodies and immunoconjugates
MA40579A (fr)	2014-09-12	2016-03-17	Genentech Inc	Anticorps anti-cll-1 et immunoconjugués
SG11201701128YA (en)	2014-09-12	2017-03-30	Genentech Inc	Cysteine engineered antibodies and conjugates
LT3191135T (lt)	2014-09-12	2020-11-25	Genentech, Inc.	Anti-her2 antikūnai ir imunokonjugatai
CN106794247B (zh)	2014-09-15	2022-12-02	豪夫迈·罗氏有限公司	抗体配制剂
MX2017003472A (es)	2014-09-17	2017-10-31	Genentech Inc	Inmunoconjugados que comprenden anticuerpos anti-her2.
HUE049175T2 (hu)	2014-09-23	2020-09-28	Hoffmann La Roche	Eljárás anti-CD79b immunkonjugátumok alkalmazására
RU2017115315A (ru)	2014-10-03	2018-11-08	Дана-Фарбер Кэнсер Инститьют, Инк.	Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
EP3204418B1 (en)	2014-10-06	2020-03-25	Dana Farber Cancer Institute, Inc.	Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
JP2017536102A (ja)	2014-10-16	2017-12-07	ジェネンテック，インコーポレイテッド	抗アルファ−シヌクレイン抗体及び使用方法
WO2016070062A2 (en)	2014-10-31	2016-05-06	Genentech, Inc.	Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
CA2966523A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Assays for detecting t cell immune subsets and methods of use thereof
US10738078B2 (en)	2014-11-03	2020-08-11	Bristol-Myers Squibb Company	Use of caprylic acid precipitation for protein purification
WO2016073380A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US11773166B2 (en)	2014-11-04	2023-10-03	Ichnos Sciences SA	CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CA2961439A1 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Anti-fgfr2/3 antibodies and methods using same
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
DK3215528T3 (da)	2014-11-06	2019-10-07	Hoffmann La Roche	Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
CR20170240A (es)	2014-11-10	2018-04-03	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos
SG10201807625PA (en)	2014-11-17	2018-10-30	Genentech Inc	Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR102614189B1 (ko)	2014-11-17	2023-12-18	리제너론 파아마슈티컬스, 인크.	Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
US10508151B2 (en)	2014-11-19	2019-12-17	Genentech, Inc.	Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en)	2014-11-19	2016-05-26	Genentech, Inc.	Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP6859259B2 (ja)	2014-11-19	2021-04-14	ジェネンテック，インコーポレイテッド	ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
CA2969067A1 (en)	2014-11-25	2016-06-02	Bristol-Myers Squibb Company	Novel pd-l1 binding polypeptides for imaging
EP3227332B1 (en)	2014-12-03	2019-11-06	F.Hoffmann-La Roche Ag	Multispecific antibodies
ES2744540T3 (es)	2014-12-05	2020-02-25	Hoffmann La Roche	Anticuerpos anti-CD79b y procedimientos de uso
ES3015000T3 (en)	2014-12-08	2025-04-28	Dana Farber Cancer Inst Inc	Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
KR20170085595A (ko)	2014-12-10	2017-07-24	제넨테크, 인크.	혈뇌 장벽 수용체 항체 및 사용 방법
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
CA2966287A1 (en)	2014-12-17	2016-06-23	F. Hoffmann-La Roche Ag	Novel methods for enzyme mediated polypeptide conjugation using sortase
AU2015364396B2 (en)	2014-12-19	2018-08-09	Alkermes, Inc.	Single chain Fc fusion proteins
KR101860280B1 (ko)	2014-12-19	2018-05-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt)	2014-12-19	2018-02-06	Chugai Pharmaceutical Co Ltd	anticorpos anti-c5 e métodos de uso
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
ES2818103T3 (es)	2015-01-16	2021-04-09	Juno Therapeutics Inc	Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
MA41374A (fr)	2015-01-20	2017-11-28	Cytomx Therapeutics Inc	Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN113956354A (zh)	2015-01-22	2022-01-21	中外制药株式会社	两种以上抗-c5抗体的组合与使用方法
AU2016209056B2 (en)	2015-01-24	2021-01-28	Academia Sinica	Cancer markers and methods of use thereof
JP6779887B2 (ja)	2015-01-24	2020-11-04	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	新規なグリカンコンジュゲートおよびその使用方法
WO2016123593A1 (en)	2015-01-30	2016-08-04	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2016215535B2 (en)	2015-02-04	2021-09-16	Boehringer Ingelheim International Gmbh	Methods of treating inflammatory diseases
EP3253784B1 (en)	2015-02-04	2020-05-06	Genentech, Inc.	Mutant smoothened and methods of using the same
KR102605798B1 (ko)	2015-02-05	2023-11-23	추가이 세이야쿠 가부시키가이샤	이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
MD1009Z (ro) *	2015-03-02	2016-09-30	Алёна НИКОРИЧ	Metodă de determinare a predispunerii persoanei la dezvoltarea limfomului non-Hodgkin
AU2016226083A1 (en)	2015-03-05	2017-10-12	Sirenas Llc	Cyclic peptide analogs and conjugates thereof
WO2016149088A1 (en)	2015-03-13	2016-09-22	Bristol-Myers Squibb Company	Use of alkaline washes during chromatography to remove impurities
CN108112254B (zh)	2015-03-13	2022-01-28	西托姆克斯治疗公司	抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016153983A1 (en)	2015-03-20	2016-09-29	Bristol-Myers Squibb Company	Use of dextran for protein purification
WO2016161390A1 (en)	2015-04-03	2016-10-06	Eureka Therapeutics, Inc.	Constructs targeting afp peptide/mhc complexes and uses thereof
KR20180002653A (ko)	2015-04-07	2018-01-08	제넨테크, 인크.	효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
KR102668588B1 (ko)	2015-04-08	2024-05-22	다나-파버 캔서 인스티튜트 인크.	인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
KR20170135972A (ko)	2015-04-14	2017-12-08	베링거 인겔하임 인터내셔날 게엠베하	질환을 치료하는 방법
HK1251655A1 (zh)	2015-04-20	2019-02-01	Tolero Pharmaceuticals, Inc.	通过线粒体分析预测对阿伏西地的应答
AU2016252771B2 (en)	2015-04-22	2021-12-16	Immunomedics, Inc.	Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
EA035332B1 (ru)	2015-04-24	2020-05-28	ВАЙВ ХЕЛТКЕР ЮКей (№5) ЛИМИТЕД	Полипептиды, нацеленные на слияние вич
CN107810197B (zh)	2015-04-24	2022-10-25	豪夫迈·罗氏有限公司	鉴定包含结合多肽的细菌的方法
WO2016172485A2 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
EP3288964B1 (en)	2015-04-27	2024-02-21	Dana-Farber Cancer Institute, Inc.	High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
JP6956639B2 (ja)	2015-05-01	2021-11-02	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法
EP3288981A1 (en)	2015-05-01	2018-03-07	Genentech, Inc.	Masked anti-cd3 antibodies and methods of use
CA2984892A1 (en)	2015-05-04	2016-11-10	Cytomx Therapeutics, Inc.	Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
BR112017023862A2 (pt)	2015-05-04	2018-07-17	Cytomx Therapeutics Inc	anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
IL292798A (en)	2015-05-04	2022-07-01	Cytomx Therapeutics Inc	Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
EP3291836A4 (en)	2015-05-06	2018-11-14	Janssen Biotech, Inc.	Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
HK1248577A1 (zh)	2015-05-11	2018-10-19	F. Hoffmann-La Roche Ag	治疗狼疮性肾炎的组合物和方法
ES2835866T5 (es)	2015-05-12	2024-12-02	Hoffmann La Roche	Procedimientos terapéuticos y de diagnóstico para el cáncer
CN115043943A (zh)	2015-05-15	2022-09-13	综合医院公司	拮抗性抗肿瘤坏死因子受体超家族抗体
KR102608921B1 (ko)	2015-05-18	2023-12-01	스미토모 파마 온콜로지, 인크.	생체 이용률이 증가된 알보시딥 프로드러그
US9708412B2 (en)	2015-05-21	2017-07-18	Harpoon Therapeutics, Inc.	Trispecific binding proteins and methods of use
HRP20201779T1 (hr)	2015-05-28	2021-01-22	Genentech, Inc.	Stanični test za otkrivanje anti-cd3 homodimera
ES2789500T5 (es)	2015-05-29	2023-09-20	Hoffmann La Roche	Procedimientos terapéuticos y de diagnóstico para el cáncer
HK1250723A1 (zh)	2015-05-29	2019-01-11	F. Hoffmann-La Roche Ag	人源化抗埃博拉病毒糖蛋白抗体和使用方法
AR105618A1 (es)	2015-05-29	2017-10-25	Genentech Inc	Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
EP3303373B1 (en)	2015-05-30	2020-04-08	Molecular Templates, Inc.	De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
TW201717935A (zh)	2015-06-03	2017-06-01	波士頓生醫公司	用於治療癌症的組成物和方法
NZ775762A (en)	2015-06-05	2025-02-28	Genentech Inc	Anti-tau antibodies and methods of use
MX2017015937A (es)	2015-06-08	2018-12-11	Genentech Inc	Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
JP2018521019A (ja)	2015-06-08	2018-08-02	ジェネンテック，インコーポレイテッド	抗ｏｘ４０抗体を使用して癌を治療する方法
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DK3310814T5 (da)	2015-06-16	2024-10-07	Hoffmann La Roche	Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse
US10501545B2 (en)	2015-06-16	2019-12-10	Genentech, Inc.	Anti-CLL-1 antibodies and methods of use
EP3916018A1 (en)	2015-06-16	2021-12-01	Genentech, Inc.	Anti-cd3 antibodies and methods of use
CN107787331B (zh)	2015-06-17	2022-01-11	豪夫迈·罗氏有限公司	抗her2抗体和使用方法
KR102689256B1 (ko)	2015-06-17	2024-07-30	제넨테크, 인크.	Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
US10774145B2 (en)	2015-06-17	2020-09-15	Allakos Inc.	Methods and compositions for treating fibrotic diseases
HUE057952T2 (hu)	2015-06-24	2022-06-28	Hoffmann La Roche	Anti-transzferrin receptor antitestek testreszabott affinitással
CN107531788B (zh)	2015-06-24	2022-06-21	豪夫迈·罗氏有限公司	对her2和血脑屏障受体特异性的三特异性抗体及使用方法
US10195175B2 (en)	2015-06-25	2019-02-05	Immunomedics, Inc.	Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US10669528B2 (en)	2015-06-25	2020-06-02	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
JP6980980B2 (ja)	2015-06-25	2021-12-15	イミューノメディクス、インコーポレイテッドImmunomedics, Inc.	抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3313885A1 (en)	2015-06-29	2018-05-02	H. Hoffnabb-La Roche Ag	Type ii anti-cd20 antibody for use in organ transplantation
EP3978525A1 (en)	2015-06-29	2022-04-06	Ventana Medical Systems, Inc.	Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
KR102669726B1 (ko)	2015-07-13	2024-05-29	라이프 테크놀로지스 코포레이션	Cho 세포에서의 개선된 일시적 단백질 발현을 위한 시스템 및 방법
JP7083497B2 (ja)	2015-08-03	2022-06-13	スミトモファーマオンコロジー，インコーポレイテッド	がんの処置のための併用療法
TWI870789B (zh)	2015-08-04	2025-01-21	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
HU231463B1 (hu)	2015-08-04	2024-01-28	Richter Gedeon Nyrt.	Módszer rekombináns proteinek galaktóz tartalmának növelésére
UA123398C2 (uk)	2015-08-05	2021-03-31	Янссен Байотек, Інк.	Виділене антагоністичне антитіло, яке специфічно зв'язує cd154, та фармацевтична композиція, яка його містить
US10509035B2 (en)	2015-08-07	2019-12-17	Gamamabs Pharma Sa	Antibodies, antibody drug conjugates and methods of use
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2018028647A1 (en)	2016-08-10	2018-02-15	Legend Biotech Usa Inc.	Chimeric antigen receptors targeting bcma and methods of use thereof
DK3334747T5 (da)	2015-08-13	2024-10-07	Amgen Inc	Ladet dybdefiltrering af antigenbindende proteiner
JP7007261B2 (ja)	2015-08-20	2022-01-24	アルブミディクスリミティド	アルブミン変異体及びコンジュゲート
CN108026180B (zh)	2015-08-28	2022-06-07	豪夫迈·罗氏有限公司	抗羟腐胺赖氨酸抗体及其用途
US10935544B2 (en)	2015-09-04	2021-03-02	Obi Pharma, Inc.	Glycan arrays and method of use
TWI799366B (zh)	2015-09-15	2023-04-21	美商建南德克公司	胱胺酸結骨架平臺
TWI811716B (zh)	2015-09-18	2023-08-11	德商百靈佳殷格翰國際股份有限公司	治療發炎性疾病之方法
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
CA2999369C (en)	2015-09-22	2023-11-07	Spring Bioscience Corporation	Anti-ox40 antibodies and diagnostic uses thereof
CN108884147B (zh)	2015-09-23	2024-02-27	百时美施贵宝公司	结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
PE20181363A1 (es)	2015-09-23	2018-08-27	Genentech Inc	Variantes optimizadas de anticuerpos anti-vegf
CN108290941A (zh)	2015-09-23	2018-07-17	百时美施贵宝公司	快解离速率的血清白蛋白结合性纤连蛋白iii型结构域
JP6955487B2 (ja)	2015-09-24	2021-10-27	アブビトロ，エルエルシー	Ｈｉｖ抗体組成物および使用方法
CN108138204B (zh)	2015-09-25	2021-12-31	豪夫迈·罗氏有限公司	使用分选酶a生产硫酯的方法
WO2017050866A1 (en)	2015-09-25	2017-03-30	F. Hoffmann-La Roche Ag	Novel soluble sortase a
PE20181046A1 (es)	2015-09-25	2018-07-03	Genentech Inc	Anticuerpos anti-tigit y metodos de uso
BR112018003594A2 (pt)	2015-09-25	2018-09-25	Hoffmann La Roche	cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
CN108026560A (zh)	2015-09-25	2018-05-11	豪夫迈·罗氏有限公司	在低共熔溶剂中使用分选酶的转酰胺反应
EP3355914B1 (en)	2015-09-29	2024-03-06	The General Hospital Corporation	A composition comprising bcg for reducing cholesterol.
BR112018006251A2 (pt)	2015-09-30	2018-10-16	Janssen Biotech Inc	anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI873952B (zh)	2015-10-02	2025-02-21	瑞士商赫孚孟拉羅股份公司	雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
WO2017055404A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific antibodies specific for pd1 and tim3
ES2895034T3 (es)	2015-10-02	2022-02-17	Hoffmann La Roche	Anticuerpos anti-PD1 y procedimientos de uso
IL293708B2 (en)	2015-10-06	2026-04-01	Genentech Inc	A method for treating multiple sclerosis
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11207393B2 (en)	2015-10-16	2021-12-28	President And Fellows Of Harvard College	Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
SG10201913990RA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10604577B2 (en)	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
HRP20220064T1 (hr)	2015-10-30	2022-04-15	F. Hoffmann - La Roche Ag	Zglobno modificirani fragmenti protutijela i postupci za pripravu
PE20181326A1 (es)	2015-11-03	2018-08-20	Janssen Biotech Inc	Anticuerpos que se unen especificamente a pd-1 y sus usos
CN118725134A (zh)	2015-11-08	2024-10-01	豪夫迈·罗氏有限公司	筛选多特异性抗体的方法
SI3383920T1 (sl)	2015-11-30	2024-06-28	The Regents Of The University Of California	Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
EP3178848A1 (en)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
IL313608A (en)	2015-12-09	2024-08-01	Hoffmann La Roche	Antibody against CD20 type II to reduce the formation of antibodies against drugs
WO2017106630A1 (en)	2015-12-18	2017-06-22	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
AR107078A1 (es)	2015-12-18	2018-03-21	Chugai Pharmaceutical Co Ltd	Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
HUE065073T2 (hu)	2015-12-18	2024-04-28	Chugai Pharmaceutical Co Ltd	Anti-C5 antitestek és alkalmazási eljárások
JP7046814B2 (ja)	2015-12-30	2022-04-04	ジェネンテック，インコーポレイテッド	タンパク質製剤のためのトリプトファン誘導体の使用
CN115400220A (zh)	2015-12-30	2022-11-29	豪夫迈·罗氏有限公司	减少聚山梨酯降解的制剂
KR20180097615A (ko)	2016-01-08	2018-08-31	에프. 호프만-라 로슈 아게	Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
CN109073635A (zh)	2016-01-25	2018-12-21	豪夫迈·罗氏有限公司	用于测定t细胞依赖性双特异性抗体的方法
EP3411396A1 (en)	2016-02-04	2018-12-12	Curis, Inc.	Mutant smoothened and methods of using the same
CN108601841A (zh)	2016-02-10	2018-09-28	免疫医疗公司	Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
JP6821693B2 (ja)	2016-02-29	2021-01-27	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
EP3423491A1 (en)	2016-03-01	2019-01-09	H. Hoffnabb-La Roche Ag	Obinutuzumab variants having altered cell death induction
EP3426693A4 (en)	2016-03-08	2019-11-13	Academia Sinica	PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
EP4049665B1 (en)	2016-03-15	2025-03-12	The Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion
US11767362B1 (en)	2016-03-15	2023-09-26	Chugai Seiyaku Kabushiki Kaisha	Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
JP7137474B2 (ja)	2016-03-15	2022-09-14	メルサナセラピューティクス，インコーポレイティド	ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
EP3430058A4 (en)	2016-03-15	2019-10-23	Generon (Shanghai) Corporation Ltd.	MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt)	2016-03-29	2019-02-12	Obi Pharma, Inc.	anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
EP3436578B1 (en)	2016-03-30	2022-01-19	F. Hoffmann-La Roche AG	Improved sortase
BR112018070948A2 (pt)	2016-04-13	2019-01-29	Orimabs Ltd.	anticorpos anti-psma e utilização dos mesmos
EP3865511A1 (en)	2016-04-14	2021-08-18	F. Hoffmann-La Roche AG	Anti-rspo3 antibodies and methods of use
JP6728392B2 (ja)	2016-04-15	2020-07-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	炎症性疾患の処置法
MX2018012472A (es)	2016-04-15	2019-08-12	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
MX2018012493A (es)	2016-04-15	2019-06-06	Genentech Inc	Métodos para controlar y tratar el cáncer.
SMT202600033T1 (it)	2016-04-15	2026-03-09	Bioatla Inc	Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
KR20190003958A (ko)	2016-04-15	2019-01-10	제넨테크, 인크.	암의 치료 및 모니터링 방법
WO2017181152A2 (en)	2016-04-15	2017-10-19	Alpine Immune Sciences, Inc.	Cd80 variant immunomodulatory proteins and uses thereof
KR102444717B1 (ko)	2016-04-15	2022-09-16	하. 룬드벡 아크티에셀스카브	인간화 항-pacap 항체 및 그의 용도
JP2019522960A (ja)	2016-04-21	2019-08-22	アッヴィ・ステムセントルクス・エル・エル・シー	新規の抗ｂｍｐｒ１ｂ抗体及び使用方法
KR20230110820A (ko)	2016-04-22	2023-07-25	오비아이 파머 인코퍼레이티드	글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
AU2017257254B2 (en)	2016-04-27	2022-02-24	Immunomedics, Inc.	Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
WO2017191101A1 (en)	2016-05-02	2017-11-09	F. Hoffmann-La Roche Ag	The contorsbody - a single chain target binder
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
PL3455261T3 (pl)	2016-05-13	2022-12-12	Bioatla, Inc.	Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
EP3493844A4 (en)	2016-05-20	2021-03-24	Harpoon Therapeutics Inc.	SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US10994033B2 (en)	2016-06-01	2021-05-04	Bristol-Myers Squibb Company	Imaging methods using 18F-radiolabeled biologics
JP7016323B2 (ja)	2016-06-01	2022-02-21	ブリストル－マイヤーズスクイブカンパニー	Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
EP3252078A1 (en)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018220099A1 (en)	2017-06-02	2018-12-06	F. Hoffmann-La Roche Ag	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
SG11201810687SA (en)	2016-06-03	2018-12-28	Janssen Biotech Inc	Serum albumin-binding fibronectin type iii domains
EP4549463A3 (en)	2016-06-17	2025-07-30	F. Hoffmann-La Roche AG	Purification of multispecific antibodies
KR102376582B1 (ko)	2016-06-17	2022-03-18	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
JP2019524706A (ja)	2016-07-08	2019-09-05	ジェネンテック，インコーポレイテッド	Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
BR112019001262A2 (pt)	2016-07-22	2019-05-07	Dana-Farber Cancer Institute, Inc.	anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos
US20190330318A1 (en)	2016-07-25	2019-10-31	Biogen Ma Inc.	Anti-hspa5 (grp78) antibodies and uses thereof
CN110072545A (zh)	2016-07-27	2019-07-30	台湾浩鼎生技股份有限公司	免疫原性/治疗性聚糖组合物及其用途
WO2018022945A1 (en)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Cd112 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Cd155 variant immunomodulatory proteins and uses thereof
JP7062640B2 (ja)	2016-07-29	2022-05-06	ジュノーセラピューティクスインコーポレイテッド	抗ｃｄ１９抗体に対する抗イディオタイプ抗体
US11643456B2 (en)	2016-07-29	2023-05-09	Obi Pharma, Inc.	Human antibodies, pharmaceutical compositions and methods
EP3494991A4 (en)	2016-08-05	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018027204A1 (en)	2016-08-05	2018-02-08	Genentech, Inc.	Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en)	2016-08-08	2018-02-15	F. Hoffmann-La Roche Ag	Therapeutic and diagnostic methods for cancer
US10947268B2 (en)	2016-08-12	2021-03-16	Bristol-Myers Squibb Company	Methods of purifying proteins
HRP20250718T1 (hr)	2016-08-15	2025-08-15	F. Hoffmann-La Roche Ag	Kromatografski postupak za kvantifikaciju neionskog surfaktanta u sastavu koji sadrži neionski surfaktant i polipeptid
CA3034057A1 (en)	2016-08-22	2018-03-01	CHO Pharma Inc.	Antibodies, binding fragments, and methods of use
CN109790220A (zh)	2016-08-25	2019-05-21	豪夫迈·罗氏有限公司	与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CA3035081A1 (en)	2016-09-02	2018-03-08	Dana-Farber Cancer Institute, Inc.	Composition and methods of treating b cell disorders
WO2018045245A1 (en)	2016-09-02	2018-03-08	Sirenas Llc	Cyclic peptide analogs and conjugates thereof
WO2018048939A1 (en)	2016-09-06	2018-03-15	Dana-Farber Cancer Institute, Inc.	Methods of treating or preventing zika virus infection
WO2018049248A1 (en)	2016-09-09	2018-03-15	Icellhealth Consulting Llc	Oncolytic virus equipped with bispecific engager molecules
EP3509616A1 (en)	2016-09-09	2019-07-17	H. Hoffnabb-La Roche Ag	Selective peptide inhibitors of frizzled
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3037144A1 (en)	2016-09-16	2018-03-22	Shanghai Henlius Biotech, Inc.	Anti-pd-1 antibodies
CN109689682B (zh)	2016-09-19	2022-11-29	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
DK3515478T3 (da) *	2016-09-21	2024-05-21	Nextcure Inc	Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
CA3038712A1 (en)	2016-10-06	2018-04-12	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
EP3526252A2 (en)	2016-10-14	2019-08-21	Boehringer Ingelheim International GmbH	Methods of treating diseases with il-23a antibody
US11078298B2 (en)	2016-10-28	2021-08-03	Banyan Biomarkers, Inc.	Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
WO2018081648A2 (en)	2016-10-29	2018-05-03	Genentech, Inc.	Anti-mic antibidies and methods of use
MY200695A (en)	2016-11-03	2024-01-11	Bristol Myers Squibb Co	Activatable anti-ctla-4 antibodies and uses thereof
WO2018083535A1 (en)	2016-11-04	2018-05-11	Novimmune Sa	Anti-cd19 antibodies and methods of use thereof
WO2018089829A1 (en)	2016-11-10	2018-05-17	Fortis Therapeutics, Inc.	Cd46-specific effector cells and uses thereof
CA3043277A1 (en)	2016-11-11	2018-05-17	The Regents Of The University Of California	Anti-cd46 antibodies and methods of use
JP7784795B2 (ja)	2016-11-15	2025-12-12	ジェネンテック，インコーポレイテッド	抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
WO2018094275A1 (en)	2016-11-18	2018-05-24	Tolero Pharmaceuticals, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
EP4015532A1 (en)	2016-11-21	2022-06-22	cureab GmbH	Anti-gp73 antibodies and immunoconjugates
TWI822055B (zh)	2016-11-21	2023-11-11	台灣浩鼎生技股份有限公司	共軛生物分子、醫藥組成物及方法
WO2018102427A1 (en)	2016-11-29	2018-06-07	Boston Biomedical, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
UA128383C2 (uk)	2016-12-07	2024-07-03	Дженентек, Інк.	Антитіло до тау-білка та спосіб його застосування
MX2019006330A (es)	2016-12-07	2019-09-26	Genentech Inc	Anticuerpos anti-tau y metodos de uso.
AU2017379847B2 (en)	2016-12-19	2022-05-26	Sumitomo Pharma Oncology, Inc.	Profiling peptides and methods for sensitivity profiling
CN110072553B (zh)	2016-12-22	2023-09-15	豪夫迈·罗氏有限公司	在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
TW201833140A (zh)	2017-01-09	2018-09-16	美商莫瑞麥克製藥公司	抗fgfr抗體及使用方法
EP3568468A4 (en)	2017-01-12	2020-12-30	Eureka Therapeutics, Inc.	RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
JP6995127B2 (ja)	2017-02-10	2022-02-04	ジェネンテック，インコーポレイテッド	抗トリプターゼ抗体、その組成物、及びその使用
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
CA3054381A1 (en)	2017-02-22	2018-08-30	University Of Saskatchewan	Egfr-binding agents and uses thereof
US20180271996A1 (en)	2017-02-28	2018-09-27	Mersana Therapeutics, Inc.	Combination therapies of her2-targeted antibody-drug conjugates
TW201837467A (zh)	2017-03-01	2018-10-16	美商建南德克公司	用於癌症之診斷及治療方法
WO2018165619A1 (en)	2017-03-09	2018-09-13	Cytomx Therapeutics, Inc.	Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
GB201703876D0 (en)	2017-03-10	2017-04-26	Berlin-Chemie Ag	Pharmaceutical combinations
SG11201907769XA (en)	2017-03-16	2019-09-27	Alpine Immune Sciences Inc	Cd80 variant immunomodulatory proteins and uses thereof
EP3596116B1 (en)	2017-03-16	2023-09-06	Alpine Immune Sciences, Inc.	Pd-l1 variant immunomodulatory proteins and uses thereof
KR20190141146A (ko)	2017-03-16	2019-12-23	알파인 이뮨 사이언시즈, 인코포레이티드	Pd-l2 변이체 면역조절 단백질 및 그의 용도
CN108467873B (zh)	2017-03-17	2020-03-13	百奥赛图江苏基因生物技术有限公司	一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
WO2018174274A1 (ja)	2017-03-24	2018-09-27	全薬工業株式会社	抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
JP2020512344A (ja)	2017-03-27	2020-04-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗ｉｌ−３６ｒ抗体併用治療
EP3600283A4 (en)	2017-03-27	2020-12-16	Immunomedics, Inc.	TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
EP3601337A1 (en)	2017-03-28	2020-02-05	Genentech, Inc.	Methods of treating neurodegenerative diseases
KR102317805B1 (ko)	2017-03-30	2021-10-27	이씨에스-프로가스트린 에스에이	전립선암을 검출하기 위한 조성물 및 방법
SG11201908996YA (en)	2017-03-30	2019-10-30	Ecs Progastrin Sa	Compositions and methods for detecting lung cancer
CN108588126B (zh)	2017-03-31	2020-04-10	北京百奥赛图基因生物技术有限公司	Cd47基因人源化改造动物模型的制备方法及应用
MX2019011769A (es)	2017-04-03	2019-11-07	Hoffmann La Roche	Anticuerpos que se unen a steap-1.
US10799597B2 (en)	2017-04-03	2020-10-13	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
TW201841916A (zh)	2017-04-12	2018-12-01	美商麥珍塔治療學股份有限公司	芳香烴受體拮抗劑及其用途
WO2018191389A1 (en)	2017-04-12	2018-10-18	Roche Sequencing Solutions, Inc.	A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction
EP3615569A1 (en)	2017-04-25	2020-03-04	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3615574A4 (en)	2017-04-26	2021-02-24	Eureka Therapeutics, Inc.	SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
SG11201909395TA (en)	2017-04-27	2019-11-28	Tesaro Inc	Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
TWI897843B (zh)	2017-05-03	2025-09-21	美商必治妥美雅史谷比公司	結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
EP3618868A4 (en)	2017-05-05	2021-02-24	Allakos Inc.	METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
EP3621994A4 (en)	2017-05-12	2020-12-30	Harpoon Therapeutics, Inc.	MESOTHELIN BINDING PROTEINS
WO2018213424A1 (en)	2017-05-17	2018-11-22	Boston Biomedical, Inc.	Methods for treating cancer
US11260117B2 (en)	2017-05-26	2022-03-01	Novimmune Sa	Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
CN110914302A (zh)	2017-06-01	2020-03-24	赛托姆克斯治疗学股份有限公司	可活化抗pdl1抗体及其使用方法
US10793634B2 (en)	2017-06-09	2020-10-06	Boehringer Ingelheim International Gmbh	Anti-TrkB antibodies
WO2019018629A1 (en)	2017-07-19	2019-01-24	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
JP2020530554A (ja)	2017-07-20	2020-10-22	シートムエックスセラピューティクス，インコーポレイテッド	活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
JP7760242B2 (ja)	2017-07-21	2025-10-27	ジェネンテック，インコーポレイテッド	がんの治療法及び診断法
IL272418B2 (en)	2017-08-08	2024-09-01	Hoffmann La Roche	Abinotuzumab treatment of a new subgroup of DLBCL patients
CA3072267A1 (en)	2017-08-09	2019-02-14	University Of Saskatchewan	Her3 binding agents and uses thereof
MX2020000903A (es)	2017-08-11	2020-07-22	Genentech Inc	Anticuerpos anti-cd8 y usos de los mismos.
US10759865B2 (en)	2017-08-22	2020-09-01	Eyal Levit	Treatment of diabetes mellitus
US11672877B2 (en)	2017-08-23	2023-06-13	Wayne State University	In vivo immunoimaging of interferon-gamma
WO2019046652A1 (en)	2017-08-30	2019-03-07	Cytomx Therapeutics, Inc.	ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
EP3681996B1 (en)	2017-09-15	2024-08-07	King's College London	Compositions and methods for enhancing gamma delta t cells in the gut
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
JP7749319B2 (ja)	2017-10-10	2025-10-06	アルパインイミューンサイエンシズインコーポレイテッド	Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
AU2018347521A1 (en)	2017-10-12	2020-05-07	Immunowake Inc.	VEGFR-antibody light chain fusion protein
MX2020003915A (es)	2017-10-13	2020-10-08	Harpoon Therapeutics Inc	Proteinas trispecificas y metodos de uso.
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
PL3691692T3 (pl)	2017-10-14	2021-07-19	Abbvie Inc.	Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania
EP3694885A1 (en)	2017-10-14	2020-08-19	CytomX Therapeutics, Inc.	Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
BR112020007542A2 (pt)	2017-10-18	2020-12-01	Alpine Immune Sciences, Inc.	proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
EP3697813A1 (en)	2017-10-20	2020-08-26	H. Hoffnabb-La Roche Ag	Copy protection for antibodies
JP7438942B2 (ja)	2017-10-30	2024-02-27	エフ．ホフマン－ラロシュアーゲー	単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
US20190314407A1 (en)	2017-10-31	2019-10-17	Magenta Therapeutics Inc.	Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3703715A1 (en)	2017-10-31	2020-09-09	Magenta Therapeutics, Inc.	Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
MX2020004196A (es)	2017-11-01	2020-11-09	Hoffmann La Roche	Trifab-contorsbody.
SG11202003501XA (en)	2017-11-01	2020-05-28	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019086394A1 (en)	2017-11-01	2019-05-09	F. Hoffmann-La Roche Ag	The compbody - a multivalent target binder
TW201923089A (zh)	2017-11-06	2019-06-16	美商建南德克公司	癌症之診斷及治療方法
EP4640703A3 (en)	2017-11-14	2026-04-08	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s antibodies and methods of use
WO2019110662A1 (en)	2017-12-05	2019-06-13	Progastrine Et Cancers S.À R.L.	Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
US20240239877A1 (en)	2017-12-18	2024-07-18	Viiv Healthcare Uk (No. 5) Limited	Antigen binding polypeptides
WO2019126536A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals Inc.	Humanized anti-cd200 antibodies and uses thereof
WO2019126133A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals, Inc.	Liquid formulations of anti-cd200 antibodies
MX2020006119A (es)	2017-12-21	2020-08-24	Hoffmann La Roche	Anticuerpos de union a hla-a2/wt1.
JP7314146B2 (ja)	2017-12-28	2023-07-25	中外製薬株式会社	細胞傷害誘導治療剤
CN117050184A (zh)	2017-12-28	2023-11-14	南京传奇生物科技有限公司	针对tigit的单域抗体和其变体
EP3731864A1 (en)	2017-12-29	2020-11-04	F. Hoffmann-La Roche SA	Anti-vegf antibodies and methods of use
AU2019205273B2 (en)	2018-01-03	2024-04-04	Alpine Immune Sciences, Inc.	Multi-domain immunomodulatory proteins and methods of use thereof
US20200338132A1 (en)	2018-01-03	2020-10-29	Magenta Therapeutics Inc.	Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
EP3735467A4 (en)	2018-01-05	2021-12-01	Ottawa Hospital Research Institute	MODIFIED VACCINE VECTORS
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN111699200B (zh)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	针对pd-1的单域抗体和其变体
EP3740505A1 (en)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispecific antibody that binds cd3 and another target
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
IL325995A (en)	2018-02-08	2026-03-01	Genentech Inc	Bispecific antigen binding molecules and methods of use
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
CN111836831A (zh)	2018-02-26	2020-10-27	豪夫迈·罗氏有限公司	用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
WO2019168897A2 (en)	2018-02-28	2019-09-06	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
WO2019173771A1 (en)	2018-03-09	2019-09-12	Cytomx Therapeutics, Inc.	Activatable cd147 antibodies and methods of making and use thereof
EP3765517A1 (en)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
EP3765522A4 (en)	2018-03-14	2022-05-18	Beijing Xuanyi Pharmasciences Co., Ltd.	ANTI-CLAUDIN 18.2 ANTIBODIES
CN112119090B (zh)	2018-03-15	2023-01-13	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
EP3774882A1 (en)	2018-03-29	2021-02-17	Bristol-Myers Squibb Company	Methods of purifying monomeric monoclonal antibodies
JP2021519073A (ja)	2018-03-29	2021-08-10	ジェネンテック，インコーポレイテッド	哺乳動物細胞におけるラクトジェニック活性の制御
TW202003567A (zh)	2018-03-30	2020-01-16	大陸商南京傳奇生物科技有限公司	針對lag-3之單一結構域抗體及其用途
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
IT201800004253A1 (it)	2018-04-05	2019-10-05		Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
JP7429192B2 (ja)	2018-04-06	2024-02-07	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
CR20250325A (es)	2018-04-13	2025-08-29	Genentech Inc	Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
JP7436383B2 (ja)	2018-04-18	2024-02-21	ユーシーエルビジネスリミテッド	操作された調節性ｔ細胞
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
WO2019213416A1 (en)	2018-05-02	2019-11-07	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
AU2019271148B9 (en)	2018-05-14	2025-05-29	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable interleukin 12 polypeptides and methods of use thereof
PE20211916A1 (es)	2018-05-24	2021-09-28	Janssen Biotech Inc	Agentes aglutinantes del psma y usos de estos
WO2019241758A1 (en)	2018-06-15	2019-12-19	Alpine Immune Sciences, Inc.	Pd-1 variant immunomodulatory proteins and uses thereof
US11993661B2 (en)	2018-06-18	2024-05-28	Eureka Therapeutics, Inc.	Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
TW202504930A (zh)	2018-06-27	2025-02-01	台灣浩鼎生技股份有限公司	用於糖蛋白工程的糖苷合成酶變體及其使用方法
WO2020006347A1 (en)	2018-06-29	2020-01-02	Boehringer Ingelheim International Gmbh	Anti-cd40 antibodies for use in treating autoimmune disease
CA3105448A1 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
MX2021000745A (es)	2018-07-20	2021-03-26	Surface Oncology Inc	Composiciones anti-cd112r y metodos.
SG11202013248YA (en)	2018-07-31	2021-02-25	Amgen Inc	Pharmaceutical formulations of masked antibodies
KR102898177B1 (ko)	2018-08-08	2025-12-10	제넨테크, 인크.	단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도
MA53272A (fr)	2018-08-10	2021-11-17	Amgen Inc	Procédé de préparation d'une formulation pharmaceutique d'anticorps
KR102259473B1 (ko)	2018-08-10	2021-06-02	추가이 세이야쿠 가부시키가이샤	항cd137 항원 결합 분자 및 그의 사용
CA3110513A1 (en)	2018-08-31	2020-03-05	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
US20210347848A1 (en)	2018-08-31	2021-11-11	ALX Oncology Inc.	Decoy polypeptides
JP2021536458A (ja)	2018-09-04	2021-12-27	マジェンタセラピューティクスインコーポレイテッドMagenta Therapeutics, Inc.	アリール炭化水素レセプター・アンタゴニスト及び使用方法
EP3847196A4 (en)	2018-09-07	2023-01-04	ITabMed (HK) Limited	BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3850013A4 (en)	2018-09-10	2022-10-05	Nanjing Legend Biotech Co., Ltd.	SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
EP3853252A1 (en)	2018-09-18	2021-07-28	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof
AU2019342099A1 (en)	2018-09-19	2021-04-08	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
KR102739487B1 (ko)	2018-09-21	2024-12-10	제넨테크, 인크.	3중-음성 유방암에 대한 진단 방법
US10815311B2 (en)	2018-09-25	2020-10-27	Harpoon Therapeutics, Inc.	DLL3 binding proteins and methods of use
US20220002370A1 (en)	2018-09-27	2022-01-06	Xilio Development, Inc.	Masked cytokine polypeptides
CN113164780A (zh)	2018-10-10	2021-07-23	泰洛斯治疗公司	抗lap抗体变体及其用途
WO2020076776A1 (en)	2018-10-10	2020-04-16	Boehringer Ingelheim International Gmbh	Method for membrane gas transfer in high density bioreactor culture
WO2020080715A1 (ko)	2018-10-15	2020-04-23	연세대학교 산학협력단	생산성이 향상된 항체 및 이의 제조방법
WO2020081493A1 (en)	2018-10-16	2020-04-23	Molecular Templates, Inc.	Pd-l1 binding proteins
EP3867646A1 (en)	2018-10-18	2021-08-25	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for sarcomatoid kidney cancer
MX2021004684A (es)	2018-10-23	2021-06-04	Glycardial Diagnostics S L	Anticuerpos especificos para apoj glucosilada y usos de los mismos.
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
US20220023439A1 (en)	2018-11-02	2022-01-27	Cytomx Therapeutics, Inc.	Activatable anti-cd166 antibodies and methods of use thereof
HU231514B1 (hu)	2018-11-07	2024-07-28	Richter Gedeon Nyrt.	Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
JP2022513082A (ja)	2018-11-19	2022-02-07	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
JP7699542B2 (ja)	2018-11-20	2025-06-27	コーネルユニバーシティー	放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
CA3120868A1 (en)	2018-11-30	2020-06-04	Alpine Immune Sciences, Inc.	Cd86 variant immunomodulatory proteins and uses thereof
US11034710B2 (en)	2018-12-04	2021-06-15	Sumitomo Dainippon Pharma Oncology, Inc.	CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CA3120327A1 (en)	2018-12-06	2020-06-11	Cytomx Therapeutics, Inc.	Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
BR112021010908A2 (pt)	2018-12-06	2021-08-31	Genentech, Inc.	Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
EP3893916A4 (en)	2018-12-11	2023-03-29	Q32 Bio Inc.	FUSION PROTEIN CONSTRUCTS FOR A COMPLEMENT-ASSOCIATED DISEASE
AR117453A1 (es)	2018-12-20	2021-08-04	Genentech Inc	Fc de anticuerpos modificados y métodos para utilizarlas
KR102910209B1 (ko)	2018-12-21	2026-01-09	제넨테크, 인크.	세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
CR20210330A (es)	2018-12-21	2021-07-20	Hoffmann La Roche	ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
WO2020132810A1 (en)	2018-12-24	2020-07-02	Generon (Shanghai) Corporation Ltd.	Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CA3122773A1 (en)	2018-12-26	2020-07-02	Xilio Development, Inc.	Anti-ctla4 antibodies and methods of use thereof
BR112021014276A2 (pt)	2019-01-22	2021-09-28	Genentech, Inc.	Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
KR102794884B1 (ko)	2019-01-23	2025-04-15	제넨테크, 인크.	진핵 숙주 세포에서 다합체 단백질을 생산하는 방법
WO2020153467A1 (ja)	2019-01-24	2020-07-30	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
SG11202107976SA (en)	2019-01-29	2021-08-30	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
WO2020160458A1 (en)	2019-02-01	2020-08-06	Avrobio, Inc.	Compositions and methods for treating neurocognitive disorders
WO2020161214A1 (en)	2019-02-07	2020-08-13	Sanofi	Use of anti-ceacam5 immunoconjugates for treating lung cancer
EP3693023A1 (en)	2019-02-11	2020-08-12	Sanofi	Use of anti-ceacam5 immunoconjugates for treating lung cancer
US12599668B2 (en)	2019-02-20	2026-04-14	Harbour Antibodies Bv	Antibodies
GB2599228B (en)	2019-02-21	2024-02-07	Marengo Therapeutics Inc	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh)	2019-02-21	2024-11-29	马伦戈治疗公司	与nkp30结合的抗体分子及其用途
EP3931563A4 (en)	2019-02-26	2022-12-21	Dana-Farber Cancer Institute, Inc.	BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING
WO2020176672A1 (en)	2019-02-26	2020-09-03	Cytomx Therapeutics, Inc.	Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
WO2020176748A1 (en)	2019-02-27	2020-09-03	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
CA3131953A1 (en)	2019-03-01	2020-09-10	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof
IL286100B2 (en)	2019-03-08	2024-12-01	Boehringer Ingelheim Int	Anti-il-36r antibody formulations
EP3938403A1 (en)	2019-03-14	2022-01-19	F. Hoffmann-La Roche AG	Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
WO2020191326A1 (en)	2019-03-20	2020-09-24	Sumitomo Dainippon Pharma Oncology, Inc.	Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN114096559B (zh)	2019-03-27	2026-03-20	蒂嘉特克斯公司	工程化iga抗体及其使用方法
US12174161B2 (en)	2019-03-29	2024-12-24	Bristol-Myers Squibb Company	Methods of measuring hydrophobicity of chromatographic resins
HU231498B1 (hu)	2019-04-04	2024-05-28	Richter Gedeon Nyrt	Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
JP7813582B2 (ja)	2019-04-18	2026-02-13	ジェネンテック，インコーポレイテッド	抗体力価試験
BR112021020867A2 (pt)	2019-04-19	2022-01-04	Genentech Inc	Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
US11591395B2 (en)	2019-04-19	2023-02-28	Janssen Biotech, Inc.	Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
CN114007643A (zh)	2019-04-19	2022-02-01	中外制药株式会社	识别抗体改变部位的嵌合受体
EP3962529A4 (en)	2019-04-30	2023-11-01	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
WO2020225400A1 (en)	2019-05-09	2020-11-12	Boehringer Ingelheim International Gmbh	Anti-sema3a antibodies and their uses for treating eye or ocular diseases
AU2020275415B2 (en)	2019-05-14	2026-01-15	Genentech, Inc.	Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
EP3969035A4 (en)	2019-05-14	2023-06-21	Werewolf Therapeutics, Inc.	SEPARATION UNITS AND METHODS AND THEIR USE
EP4696320A2 (en)	2019-05-15	2026-02-18	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s antibody
AR119264A1 (es)	2019-06-05	2021-12-09	Genentech Inc	Método para reutilización de cromatografía
EP3983447A4 (en)	2019-06-14	2023-06-28	Dana-Farber Cancer Institute, Inc.	Antibodies against muc1 and methods of use thereof
EP3986917A1 (en)	2019-06-20	2022-04-27	CSPC Megalith Biopharmaceutical Co., Ltd.	Modified il-2 proteins, peg conjugates, and uses thereof
TWI877179B (zh)	2019-06-27	2025-03-21	德商百靈佳殷格翰國際股份有限公司	抗-angpt2抗體
MX2022000111A (es)	2019-07-10	2022-02-10	Chugai Pharmaceutical Co Ltd	Moleculas de union a claudina-6 y usos de las mismas.
WO2021010326A1 (ja)	2019-07-12	2021-01-21	中外製薬株式会社	抗変異型ｆｇｆｒ３抗体およびその使用
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
WO2021014389A1 (en)	2019-07-24	2021-01-28	H. Lundbeck A/S	Anti-mglur5 antibodies and uses thereof
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
CA3248329A1 (en)	2019-07-31	2025-11-29	F. Hoffmann-La Roche Ag	Antibodies binding to gprc5d
CN114174338A (zh)	2019-07-31	2022-03-11	豪夫迈·罗氏有限公司	与gprc5d结合的抗体
DE102019121007A1 (de)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Recruiting agent further binding an mhc molecule
JP7181438B2 (ja)	2019-08-06	2022-11-30	アプリノイアセラピューティクスリミテッド	病理学的タウ種に結合する抗体及びその使用
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
TWI873176B (zh)	2019-09-04	2025-02-21	美商建南德克公司	Ｃｄ８結合劑及其用途
TW202535466A (zh)	2019-09-09	2025-09-16	德商百靈佳殷格翰國際股份有限公司	抗-il-23p19抗體調配物
PH12022550646A1 (en)	2019-09-18	2023-04-03	Genentech Inc	Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
JP2022548310A (ja)	2019-09-23	2022-11-17	シートムエックスセラピューティクス，インコーポレイテッド	抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
TWI859339B (zh)	2019-09-24	2024-10-21	德商百靈佳殷格翰國際股份有限公司	抗nrp1a抗體及其用於治療眼或眼部疾病之用途
JP2022548978A (ja)	2019-09-27	2022-11-22	ジェネンテック，インコーポレイテッド	薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
EP4017542A1 (en)	2019-10-04	2022-06-29	Tae Life Sciences	Antibody compositions comprising fc mutations and site-specific conjugation properties
WO2021076196A1 (en)	2019-10-18	2021-04-22	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US12297451B1 (en)	2019-10-25	2025-05-13	Regeneron Pharmaceuticals, Inc.	Cell culture medium
KR20220092580A (ko)	2019-11-06	2022-07-01	제넨테크, 인크.	혈액암의 치료를 위한 진단과 치료 방법
MX2022005666A (es)	2019-11-14	2022-10-07	Werewolf Therapeutics Inc	Polipeptidos de citocina activables y metodos de uso de los mismos.
CA3152314A1 (en)	2019-11-15	2021-05-20	Andrea ALLMENDINGER	Prevention of visible particle formation in aqueous protein solutions
CN115916817A (zh)	2019-12-06	2023-04-04	朱诺治疗学股份有限公司	针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
EP4069742A1 (en)	2019-12-06	2022-10-12	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2021119505A1 (en)	2019-12-13	2021-06-17	Genentech, Inc.	Anti-ly6g6d antibodies and methods of use
KR20220100963A (ko)	2019-12-18	2022-07-18	에프. 호프만-라 로슈 아게	Hla-a2/mage-a4에 결합하는 항체
CN115175691B (zh)	2019-12-18	2026-02-10	Aro生物疗法公司	结合血清白蛋白的纤连蛋白iii型结构域及其应用
KR20220118527A (ko)	2019-12-23	2022-08-25	제넨테크, 인크.	아포지질단백질 l1-특이적 항체 및 이용 방법
UA128549C2 (uk)	2019-12-27	2024-08-07	Чугаі Сейяку Кабусікі Кайся	Антитіло до ctla-4 та його застосування
AU2020416273A1 (en)	2020-01-03	2022-07-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
WO2021141996A1 (en)	2020-01-06	2021-07-15	Cytomx Therapeutics, Inc.	Single- and multi-chain polypeptides that bind specifically to cd3 epsilon
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
EP4090365A1 (en)	2020-01-15	2022-11-23	Immatics Biotechnologies GmbH	Antigen binding proteins specifically binding prame
EP4093513A4 (en)	2020-01-24	2024-05-08	Dana-Farber Cancer Institute, Inc.	Uses of biomarkers for improving immunotherapy
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4096713A1 (en)	2020-01-31	2022-12-07	Seagen Inc.	Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
WO2021174045A1 (en)	2020-02-28	2021-09-02	Bristol-Myers Squibb Company	Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
KR20220148235A (ko)	2020-02-28	2022-11-04	젠자임 코포레이션	최적화된 약물 접합을 위한 변형된 결합 폴리펩티드
GB202003632D0 (en)	2020-03-12	2020-04-29	Harbour Antibodies Bv	SARS-Cov-2 (SARS2, COVID-19) antibodies
PE20230252A1 (es)	2020-03-13	2023-02-07	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos de estos
CN117551194A (zh)	2020-03-19	2024-02-13	基因泰克公司	同种型选择性抗TGF-β抗体及使用方法
JP2023518841A (ja)	2020-03-26	2023-05-08	ジェネンテック，インコーポレイテッド	宿主細胞タンパク質が減少した修飾哺乳動物細胞
WO2021202727A2 (en)	2020-03-31	2021-10-07	Repertoire Immune Medicines, Inc.	Barcodable exchangeable peptide-mhc multimer libraries
US12523662B2 (en)	2020-04-02	2026-01-13	Seattle Children's Hospital	Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
WO2021202959A1 (en)	2020-04-03	2021-10-07	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
US20230272056A1 (en)	2020-04-09	2023-08-31	Merck Sharp & Dohme Llc	Affinity matured anti-lap antibodies and uses thereof
WO2021207669A1 (en)	2020-04-10	2021-10-14	Cytomx Therapeutics, Inc.	Activatable cytokine constructs and related compositions and methods
MX2022013406A (es)	2020-04-24	2022-11-14	Sanofi Sa	Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
CN115916822A (zh)	2020-04-24	2023-04-04	基因泰克公司	使用抗CD79b免疫缀合物的方法
AU2021258464A1 (en)	2020-04-24	2023-01-05	Sanofi	Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil
CA3181005A1 (en)	2020-04-24	2021-10-28	Sanofi	Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox
EP4138924A1 (en)	2020-04-24	2023-03-01	Sanofi	Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
EP4143345A1 (en)	2020-04-28	2023-03-08	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
EP4146797A1 (en)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Treatment for neurodegenerative diseases
CN115605184A (zh)	2020-05-15	2023-01-13	豪夫迈·罗氏有限公司（Ch）	防止胃肠外蛋白质溶液中的可见颗粒形成
EP4153130A1 (en)	2020-05-19	2023-03-29	F. Hoffmann-La Roche AG	The use of chelators for the prevention of visible particle formation in parenteral protein solutions
GB202007842D0 (en)	2020-05-26	2020-07-08	Quell Therapeutics Ltd	Polypeptide useful in adoptive cell therapy
CR20220596A (es)	2020-05-26	2023-01-23	Boehringer Ingelheim Int	Anticuerpos anti-pd-1
MX2022015651A (es)	2020-06-11	2023-01-16	Genentech Inc	Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos.
JP2023529206A (ja)	2020-06-12	2023-07-07	ジェネンテック，インコーポレイテッド	がん免疫療法のための方法及び組成物
AU2021293038A1 (en)	2020-06-16	2023-02-02	F. Hoffmann-La Roche Ag	Methods and compositions for treating triple-negative breast cancer
KR20230024368A (ko)	2020-06-18	2023-02-20	제넨테크, 인크.	항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
PE20230835A1 (es)	2020-06-19	2023-05-19	Hoffmann La Roche	Anticuerpos que se unen a cd3
WO2021255155A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cd19
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
PH12022553489A1 (en)	2020-06-19	2024-04-22	Hoffmann La Roche	Antibodies binding to cd3 and folr1
CA3184747A1 (en)	2020-06-24	2021-12-30	Genentech, Inc.	Apoptosis resistant cell lines
US20240409617A1 (en)	2020-07-03	2024-12-12	Dana-Farber Cancer Institute, Inc.	Multispecific coronavirus antibodies
CN116133689A (zh)	2020-07-07	2023-05-16	豪夫迈·罗氏有限公司	作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
KR20230035576A (ko)	2020-07-07	2023-03-14	비온테크 에스이	Hpv 양성 암 치료용 rna
KR20230050336A (ko)	2020-07-10	2023-04-14	인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)	뇌전증을 치료하기 위한 방법과 조성물
TW202204895A (zh)	2020-07-13	2022-02-01	美商建南德克公司	預測多肽免疫性的基於細胞之方法
JP7846667B2 (ja)	2020-07-16	2026-04-15	レジェンドバイオテックアイルランドリミテッド	Ｃｄ２０結合分子及びその使用
PH12023550112A1 (en)	2020-07-17	2024-06-24	Genentech Inc	Anti-notch2 antibodies and methods of use
WO2022020353A2 (en)	2020-07-20	2022-01-27	Dana-Farber Cancer Institute, Inc.	Methods and compositions for treatment and prevention of coronavirus infection
EP4192868A1 (en)	2020-08-05	2023-06-14	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
EP4192942A1 (en)	2020-08-07	2023-06-14	Genentech, Inc.	T cell-based methods for predicting polypeptide immunogenicity
EP4192511A1 (en)	2020-08-07	2023-06-14	Fortis Therapeutics, Inc.	Immunoconjugates targeting cd46 and methods of use thereof
BR112023002123A2 (pt)	2020-08-07	2023-03-07	Genentech Inc	Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo
IL300534A (en)	2020-08-11	2023-04-01	Kanaph Therapeutics Inc	A fusion protein containing 12-il and an anti-fap antibody, and its use
GB202013477D0 (en)	2020-08-27	2020-10-14	Quell Therapeutics Ltd	Nucleic acid constructs for expressing polypeptides in cells
CA3192344A1 (en)	2020-08-28	2022-03-03	Genentech, Inc.	Crispr/cas9 multiplex knockout of host cell proteins
AU2021335257A1 (en)	2020-09-04	2023-03-09	Merck Patent Gmbh	Anti-CEACAM5 antibodies and conjugates and uses thereof
CN116406291A (zh)	2020-10-05	2023-07-07	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
US12006550B2 (en)	2020-10-12	2024-06-11	University Of South Carolina	Targeting treatment for ADAM30 in pathological cells
AR123855A1 (es)	2020-10-20	2023-01-18	Genentech Inc	Anticuerpos anti-mertk conjugados con peg y métodos de uso
WO2022087154A1 (en)	2020-10-20	2022-04-28	Repertoire Immune Medicines, Inc.	Mhc class ii peptide multimers and uses thereof
AU2021374594B2 (en)	2020-11-04	2026-03-05	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
TWI874719B (zh)	2020-11-04	2025-03-01	美商建南德克公司	用抗cd20/抗cd3雙特異性抗體進行治療之給藥
JP7716473B2 (ja)	2020-11-04	2025-07-31	ジェネンテック，インコーポレイテッド	抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
IL302412A (en)	2020-11-06	2023-06-01	Novartis Ag	Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
AU2021379882A1 (en)	2020-11-10	2023-06-29	Sanofi	Ceacam5 antibody-drug conjugate formulation
WO2022115865A2 (en)	2020-11-25	2022-06-02	Xilio Development, Inc.	Tumor-specific cleavable linkers
WO2022116877A1 (en)	2020-12-02	2022-06-09	Shanghai Henlius Biotech, Inc.	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
MX2023007133A (es)	2020-12-17	2023-06-27	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de estos.
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022140797A1 (en)	2020-12-23	2022-06-30	Immunowake Inc.	Immunocytokines and uses thereof
US20250282870A1 (en)	2021-01-20	2025-09-11	Bioentre Llc	Ctla4-binding proteins and methods of treating cancer
JP2024503933A (ja)	2021-01-27	2024-01-29	イノベントバイオロジクス（スーチョウ）カンパニー，リミティド	Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
EP4284838A2 (en)	2021-01-28	2023-12-06	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
WO2022169872A1 (en)	2021-02-03	2022-08-11	Genentech, Inc.	Multispecific binding protein degrader platform and methods of use
CN117062836A (zh)	2021-02-05	2023-11-14	勃林格殷格翰国际有限公司	抗il1rap抗体
EP4301467A1 (en)	2021-03-01	2024-01-10	Xilio Development, Inc.	Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CA3209364A1 (en)	2021-03-01	2022-09-09	Jennifer O'neil	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
IL305758A (en)	2021-03-10	2023-11-01	Immunowake Inc	Immunomodulatory compounds and their uses
WO2022192647A1 (en)	2021-03-12	2022-09-15	Genentech, Inc.	Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
BR112023018735A2 (pt)	2021-03-16	2023-11-28	Cytomx Therapeutics Inc	Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
US12448444B2 (en)	2021-03-22	2025-10-21	Novimmune Sa	Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
IL305828A (en)	2021-03-22	2023-11-01	Novimmune Sa	Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
EP4314049A1 (en)	2021-03-25	2024-02-07	Dynamicure Biotechnology LLC	Anti-igfbp7 constructs and uses thereof
US20240209080A1 (en)	2021-04-10	2024-06-27	Profoundbio Us Co.	Folr1 binding agents, conjugates thereof and methods of using the same
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
EP4326855A1 (en)	2021-04-19	2024-02-28	Genentech, Inc.	Modified mammalian cells
CA3216459A1 (en)	2021-04-23	2022-10-27	Profoundbio Us Co.	Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202244059A (zh)	2021-04-30	2022-11-16	瑞士商赫孚孟拉羅股份公司	用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
CA3213632A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US20240262917A1 (en)	2021-05-06	2024-08-08	Dana-Farber Cancer Institute, Inc.	Antibodies against alk and methods of use thereof
IL308296A (en)	2021-05-07	2024-01-01	Viela Bio Inc	Use of anti-CD19 antibody to treat myasthenia gravis
WO2022239720A1 (ja)	2021-05-10	2022-11-17	公益財団法人川崎市産業振興財団	抗原への結合親和性を低減させた抗体
IL308351A (en)	2021-05-12	2024-01-01	Genentech Inc	Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
CN117396599A (zh)	2021-05-21	2024-01-12	基因泰克公司	用于生产目的重组产物的经修饰的细胞
TW202306994A (zh)	2021-06-04	2023-02-16	日商中外製藥股份有限公司	抗ddr2抗體及其用途
AU2021449810A1 (en)	2021-06-08	2023-12-07	Xyphos Biosciences Inc.	Antibody-nkg2d ligand domain fusion protein
US20240280561A1 (en)	2021-06-08	2024-08-22	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CN117412768A (zh)	2021-06-08	2024-01-16	修普霍斯生物科学有限公司	抗体-nkg2d配体结构域融合蛋白
TWI879694B (zh)	2021-06-25	2025-04-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
AR126220A1 (es)	2021-06-25	2023-09-27	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-ctla-4
TW202320857A (zh)	2021-07-06	2023-06-01	美商普方生物製藥美國公司	連接子、藥物連接子及其結合物及其使用方法
CA3225254A1 (en)	2021-07-13	2023-01-19	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
KR20240038773A (ko)	2021-07-27	2024-03-25	아스트라제네카 아베	루푸스의 치료
CN117794953A (zh)	2021-08-03	2024-03-29	豪夫迈·罗氏有限公司	双特异性抗体及使用方法
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3228916A1 (en)	2021-08-11	2023-02-16	King's College London	Compositions and methods for improved treatment of disorders affecting the central nervous system
JP2024534151A (ja)	2021-08-27	2024-09-18	ジェネンテック，インコーポレイテッド	タウ病態の治療方法
WO2023036982A1 (en)	2021-09-10	2023-03-16	Harbour Antibodies Bv	Anti-sars2-s antibodies
GB202112935D0 (en)	2021-09-10	2021-10-27	Harbour Antibodies Bv	Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
EP4413998A4 (en)	2021-10-08	2026-02-25	Chugai Pharmaceutical Co Ltd	METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
TW202334185A (zh)	2021-10-08	2023-09-01	美商Ｃｙｔｏｍｘ生物製藥公司	可經活化之細胞介素構築體和組合方法
IL311971A (en)	2021-10-08	2024-06-01	Cytomx Therapeutics Inc	Activatable cytokine constructs and related compositions and methods
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
AR127343A1 (es)	2021-10-13	2024-01-31	Cytomx Therapeutics Inc	Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados
AU2022382383A1 (en)	2021-11-05	2024-06-20	Eli Lilly And Company	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
WO2023081471A1 (en)	2021-11-05	2023-05-11	Dana-Farber Cancer Institute, Inc.	Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
TW202337494A (zh)	2021-11-16	2023-10-01	美商建南德克公司	用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
JP2024541476A (ja)	2021-11-24	2024-11-08	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｃｔｌａ－４に対する抗体及びその使用方法
WO2023097119A2 (en)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
EP4440603A1 (en)	2021-12-02	2024-10-09	Sanofi	Cea assay for patient selection in cancer therapy
AU2022402334A1 (en)	2021-12-02	2024-07-18	Sanofi	Ceacam5 adc–anti-pd1/pd-l1 combination therapy
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
CA3241395A1 (en)	2021-12-17	2023-06-22	Barbel SCHROFELBAUER	Antibodies and uses thereof
CA3241407A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
KR20240116755A (ko)	2021-12-17	2024-07-30	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
KR20240122784A (ko)	2021-12-17	2024-08-13	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체 및 사용 방법
CR20240265A (es)	2021-12-22	2024-10-16	Boehringer Ingelheim Int	Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
GB2614309A (en)	2021-12-24	2023-07-05	Stratosvir Ltd	Improved vaccinia virus vectors
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
US20230322958A1 (en)	2022-01-19	2023-10-12	Genentech, Inc.	Anti-Notch2 Antibodies and Conjugates and Methods of Use
CN119212728A (zh)	2022-02-04	2024-12-27	丹娜-法伯癌症研究院	用于处理神经病的组合物和方法
AU2023221861A1 (en)	2022-02-18	2024-09-05	Rakuten Medical, Inc.	Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
EP4238988A1 (en)	2022-03-01	2023-09-06	Consejo Superior De Investigaciones Científicas	Antibodies against sars-cov-2 and uses thereof
WO2023172883A1 (en)	2022-03-07	2023-09-14	Alpine Immune Sciences, Inc.	Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
US20250179210A1 (en)	2022-03-09	2025-06-05	Merck Patent Gmbh	Anti-ceacam5 antibodies and conjugates and uses thereof
WO2023172968A1 (en)	2022-03-09	2023-09-14	Merck Patent Gmbh	Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
EP4493592A1 (en)	2022-03-14	2025-01-22	LamKap Bio gamma AG	Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
WO2023175171A1 (en)	2022-03-18	2023-09-21	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Bk polyomavirus antibodies and uses thereof
WO2023178357A1 (en)	2022-03-18	2023-09-21	Evolveimmune Therapeutics, Inc.	Bispecific antibody fusion molecules and methods of use thereof
MX2024011468A (es)	2022-03-23	2024-09-25	Hoffmann La Roche	Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
JP2025512798A (ja)	2022-03-25	2025-04-22	サイトムエックスセラピューティクス，インク．	活性化可能な二重アンカー型マスク化分子及びその使用方法
CA3245762A1 (en)	2022-03-25	2023-09-28	Shanghai Henlius Biologics Co., Ltd.	ANTI-MSLN ANTIBODIES AND METHODS OF USE
EP4504782A2 (en)	2022-04-01	2025-02-12	CytomX Therapeutics, Inc.	Cd3-binding proteins and methods of use thereof
IL315770A (en)	2022-04-01	2024-11-01	Genentech Inc	Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
WO2023192973A1 (en)	2022-04-01	2023-10-05	Cytomx Therapeutics, Inc.	Activatable multispecific molecules and methods of use thereof
WO2023198727A1 (en)	2022-04-13	2023-10-19	F. Hoffmann-La Roche Ag	Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023201299A1 (en)	2022-04-13	2023-10-19	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
AU2023264069A1 (en)	2022-05-03	2024-10-24	Genentech, Inc.	Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023215498A2 (en)	2022-05-05	2023-11-09	Modernatx, Inc.	Compositions and methods for cd28 antagonism
JP2025517650A (ja)	2022-05-11	2025-06-10	ジェネンテック，インコーポレイテッド	抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
KR20250022049A (ko)	2022-06-07	2025-02-14	제넨테크, 인크.	항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
WO2023240287A1 (en)	2022-06-10	2023-12-14	Bioentre Llc	Combinations of ctla4 binding proteins and methods of treating cancer
CN119384426A (zh)	2022-06-17	2025-01-28	基因泰克公司	亲液剂用以提高亲和色谱纯化步骤的产率的用途
AU2023305619A1 (en)	2022-07-13	2025-01-23	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20250040020A (ko)	2022-07-19	2025-03-21	제넨테크, 인크.	항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
TW202417504A (zh)	2022-07-22	2024-05-01	美商建南德克公司	抗ｓｔｅａｐ１抗原結合分子及其用途
EP4565250A1 (en)	2022-08-01	2025-06-11	CytomX Therapeutics, Inc.	Protease-cleavable substrates and methods of use thereof
JP2025525868A (ja)	2022-08-01	2025-08-07	サイトムエックスセラピューティクス，インク．	プロテアーゼ切断性部分及びその使用方法
AR130078A1 (es)	2022-08-01	2024-10-30	Cytomx Therapeutics Inc	Substratos escindibles por proteasas, y métodos de uso de los mismos
JP2025525880A (ja)	2022-08-01	2025-08-07	サイトムエックスセラピューティクス，インク．	プロテアーゼ切断性部分及びその使用方法
JP2025525867A (ja)	2022-08-01	2025-08-07	サイトムエックスセラピューティクス，インク．	プロテアーゼ切断性部分及びその使用方法
EP4572785A1 (en)	2022-08-15	2025-06-25	Dana-Farber Cancer Institute, Inc.	Antibodies against cldn4 and methods of use thereof
AU2023324669A1 (en)	2022-08-15	2025-02-13	Dana-Farber Cancer Institute, Inc.	Antibodies against msln and methods of use thereof
EP4577578A1 (en)	2022-08-22	2025-07-02	Abdera Therapeutics Inc.	Dll3 binding molecules and uses thereof
WO2024044779A2 (en)	2022-08-26	2024-02-29	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
EP4581366A1 (en)	2022-09-01	2025-07-09	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
CA3267488A1 (en)	2022-09-16	2024-03-21	King's College London	COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
WO2024077089A2 (en)	2022-10-04	2024-04-11	Siren Biotechnology, Inc.	Modified cpg dinucleotides for recombinant viral vector production
TW202430228A (zh)	2022-10-10	2024-08-01	法商尤尼克爾法國公司	治療癲癇之方法及組成物
US20240254234A1 (en)	2022-10-21	2024-08-01	Novimmune Sa	PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
KR20250093336A (ko)	2022-10-25	2025-06-24	제넨테크, 인크.	다발성 골수종에 대한 치료 및 진단 방법
TW202417057A (zh)	2022-10-26	2024-05-01	大陸商同潤生物醫藥(上海)有限公司	人源化的l1cam抗體藥物偶聯物
WO2024097639A1 (en)	2022-10-31	2024-05-10	Modernatx, Inc.	Hsa-binding antibodies and binding proteins and uses thereof
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
WO2024102948A1 (en)	2022-11-11	2024-05-16	Celgene Corporation	Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
WO2024118866A1 (en)	2022-12-01	2024-06-06	Modernatx, Inc.	Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
KR20250135354A (ko)	2022-12-13	2025-09-12	주노 쎄러퓨티크스 인코퍼레이티드	Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
JP2026501506A (ja)	2022-12-14	2026-01-16	アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ	Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
EP4634381A1 (en)	2022-12-14	2025-10-22	King's College London	Compositions and methods for treating neurological diseases
WO2024147114A1 (en)	2023-01-06	2024-07-11	Bloomsbury Genetic Therapies Limited	Compositions and methods for treating parkinson's disease
CN120569410A (zh)	2023-01-25	2025-08-29	豪夫迈·罗氏有限公司	与csf1r和cd3结合的抗体
WO2024161022A2 (en)	2023-02-03	2024-08-08	King's College London	Compositions and methods for treating neurological diseases
JP2026508856A (ja)	2023-03-01	2026-03-13	サノフイ	Ｃｅａｃａｍ５を発現する神経内分泌がんを処置するための抗ｃｅａｃａｍ５免疫複合体の使用
EP4427763A1 (en)	2023-03-06	2024-09-11	Sanofi	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
KR20250169564A (ko)	2023-03-23	2025-12-03	사노피	암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정
WO2024206329A1 (en)	2023-03-27	2024-10-03	Modernatx, Inc.	Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024206126A1 (en)	2023-03-27	2024-10-03	Modernatx, Inc.	Cd16-binding antibodies and uses thereof
CN120936626A (zh)	2023-03-31	2025-11-11	基因泰克公司	抗αvβ8整合素抗体及使用方法
WO2024216170A2 (en)	2023-04-12	2024-10-17	Cytomx Therapeutics, Inc.	Activatable cytokine constructs and related compositions and methods
EP4695281A1 (en)	2023-04-12	2026-02-18	CytomX Therapeutics, Inc.	Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN120936384A (zh)	2023-04-12	2025-11-11	西托姆克斯治疗公司	掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
AU2024270495A1 (en)	2023-05-05	2025-10-09	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024236167A1 (en)	2023-05-17	2024-11-21	Morphosys Ag	Il-13 receptor alpha 2 binding polypeptides
WO2024236163A1 (en)	2023-05-17	2024-11-21	Morphosys Ag	T cell receptor beta constant region 2 (trbc2) antibodies
EP4719483A1 (en)	2023-06-05	2026-04-08	Sanofi	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies
KR20260021689A (ko)	2023-06-08	2026-02-13	제넨테크, 인크.	림프종 진단 및 치료 방법을 위한 대식세포 시그니처
AU2024304180A1 (en)	2023-06-13	2026-01-08	Adcentrx Therapeutics, Inc.	Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
US12319747B2 (en)	2023-07-03	2025-06-03	Medicovestor, Inc.	Methods of using anti-SP17 immunotherapeutics
AU2024300993A1 (en)	2023-07-26	2026-01-22	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2025038600A1 (en)	2023-08-14	2025-02-20	Amgen Inc.	Methods for reducing yellow color
WO2025049272A1 (en)	2023-08-25	2025-03-06	The Broad Institute, Inc.	Card9 variant polypeptide and antibodies directed thereto
AU2024341660A1 (en)	2023-09-11	2026-03-12	Evolveimmune Therapeutics, Inc.	Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
AU2024345039A1 (en)	2023-09-20	2026-03-19	Evolveimmune Therapeutics, Inc.	Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025064890A1 (en)	2023-09-20	2025-03-27	Evolveimmune Therapeutics, Inc.	Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
AR133909A1 (es)	2023-09-25	2025-11-12	Hoffmann La Roche	ANTICUERPO QUE SE UNE A C3bBb
AR133955A1 (es)	2023-09-26	2025-11-19	Profoundbio Us Co	Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
US20250109209A1 (en)	2023-10-03	2025-04-03	Absci Corporation	Tl1a associated antibody compositions and methods of use
US12364777B2 (en)	2023-10-20	2025-07-22	Medicovestor, Inc.	Homodimeric antibodies for use in treating cancers and methods of use
WO2025082618A1 (en)	2023-10-20	2025-04-24	Fuse Vectors Aps	In vitro parvovirus capsid manufacturing
WO2025087681A1 (en)	2023-10-26	2025-05-01	Morphosys Ag	Bispecific antibodies against cd3 and cd20
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025114357A1 (en)	2023-11-28	2025-06-05	Novimmune Sa	Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
US20250179207A1 (en)	2023-11-30	2025-06-05	Genzyme Corporation	Methods for treating digitally-identified cd20-related disorders
TW202541837A (zh)	2023-12-08	2025-11-01	日商安斯泰來製藥公司	含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025122885A1 (en)	2023-12-08	2025-06-12	Absci Corporation	Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en)	2024-08-08	2026-02-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025125386A1 (en)	2023-12-14	2025-06-19	F. Hoffmann-La Roche Ag	Antibodies that bind to folr1 and methods of use
WO2025126153A2 (en)	2023-12-14	2025-06-19	Aviadobio Ltd.	Compositions and methods for treating sod1-mediated neurological diseases
WO2025132503A1 (en)	2023-12-20	2025-06-26	F. Hoffmann-La Roche Ag	Antibodies binding to ceacam5
US12600795B2 (en)	2023-12-26	2026-04-14	Medicovestor, Inc.	Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en)	2023-12-26	2024-10-15	Medicovestor, Inc.	Methods of manufacturing dimeric antibodies
WO2025149661A1 (en)	2024-01-10	2025-07-17	Genmab A/S	Slitrk6 binding agents, conjugates thereof and methods of using the same
US12240900B1 (en)	2024-02-02	2025-03-04	Medicovestor, Inc.	Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12258396B1 (en)	2024-02-02	2025-03-25	Medicovestor, Inc.	Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en)	2024-02-02	2025-08-05	Medicovestor, Inc.	Proteins that bind folate receptor alpha including fully-human antibodies
WO2025169012A1 (en)	2024-02-06	2025-08-14	Sanofi	Methods of treating ceacam5-expressing cancers
TW202600175A (zh)	2024-02-15	2026-01-01	德商馬克專利公司	用於治療gd2陽性癌症之抗gd2抗體及免疫結合物
WO2025176877A1 (en)	2024-02-22	2025-08-28	Astrazeneca Ab	Therapeutic combination of an akt inhibitor, a bcl-2 inhibitor, and an anti-cd20 antibody
WO2025177263A1 (en)	2024-02-25	2025-08-28	Biohaven Therapeutics Ltd.	Myostatin-binding proteins
US12521446B2 (en)	2024-02-27	2026-01-13	Bristol-Myers Squibb Company	Anti-CEACAM5 antibody drug conjugates
WO2025184208A1 (en)	2024-02-27	2025-09-04	Bristol-Myers Squibb Company	Anti-ceacam5 antibodies and uses thereof
WO2025184421A1 (en)	2024-02-28	2025-09-04	Juno Therapeutics, Inc.	Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
US20250381289A1 (en)	2024-02-29	2025-12-18	Genmab A/S	Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025210264A1 (en)	2024-04-04	2025-10-09	Merck Patent Gmbh	Antibody-drug-conjugates binding napi2b
WO2025215060A1 (en)	2024-04-11	2025-10-16	F. Hoffmann-La Roche Ag	Antibodies that specifically bind modified oligonucleotides
WO2025240659A2 (en)	2024-05-14	2025-11-20	Cytomx Therapeutics, Inc.	Activatable constructs, compositions and methods
WO2025242845A1 (en)	2024-05-22	2025-11-27	Merck Patent Gmbh	Colorectal cancer treatment
EP4653460A1 (en)	2024-05-23	2025-11-26	Egle Therapeutics	Il18r agonist antibodies and uses thereof
WO2025242910A1 (en)	2024-05-23	2025-11-27	Egle Therapeutics	Il18r agonist antibodies and uses thereof
WO2025264533A1 (en)	2024-06-17	2025-12-26	Adcentrx Therapeutics Inc.	Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2026020161A1 (en)	2024-07-19	2026-01-22	Cytomx Therapeutics, Inc.	Activatable il-12 constructs and related compositions and methods
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026035650A2 (en)	2024-08-05	2026-02-12	Cytomx Therapeutics, Inc.	Cleavable polypeptides and methods of use thereof
WO2026033259A1 (en)	2024-08-05	2026-02-12	Lys Therapeutics	Antibodies for treating neurological and neurovascular disorders
WO2026036019A1 (en)	2024-08-09	2026-02-12	Life Technologies Corporation	Method of producing a recombinant protein in hek-293 cells
WO2026041568A1 (en)	2024-08-20	2026-02-26	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and dotam
WO2026052582A1 (en)	2024-09-04	2026-03-12	Red Ridge Bio Ag	Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3
WO2026082894A1 (en)	2024-10-17	2026-04-23	Sanofi	Ceacam5 antibody-drug conjugate for use in cancer therapy
WO2026082966A1 (en)	2024-10-18	2026-04-23	Novimmune Sa	Methods of treating disease using anti-cd47 x anti-mesothelin antibodies in combination with chemotherapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
DE3689123T2 (de)	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5099069A (en) *	1986-09-05	1992-03-24	Gansow Otto A	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) *	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) *	1986-09-05	1993-09-21	The United States Of America As Represented By The Secretary Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
USRE38008E1 (en) *	1986-10-09	2003-02-25	Neorx Corporation	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) *	1986-10-27	2005-05-17	Royalty Pharma Finance Trust	Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1341235C (en)	1987-07-24	2001-05-22	Randy R. Robinson	Modular assembly of antibody genes, antibodies prepared thereby and use
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5439665A (en) *	1988-07-29	1995-08-08	Immunomedics	Detection and treatment of infectious and inflammatory lesions
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5460785A (en) *	1989-08-09	1995-10-24	Rhomed Incorporated	Direct labeling of antibodies and other protein with metal ions
SE8903003D0 (sv)	1989-09-12	1989-09-12	Astra Ab	Novel medical use
US5124471A (en) *	1990-03-26	1992-06-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Bifunctional dtpa-type ligand
GB9014932D0 (en) *	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
WO1992007466A1 (en)	1990-11-05	1992-05-14	Bristol-Myers Squibb Company	Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
DE4124248A1 (de)	1991-07-22	1993-01-28	Henkel Kgaa	Verfahren zur selektiven fettspaltung, dazu geeignete lipasemischung und mikroorganismus
ES2196002T3 (es)	1991-07-25	2003-12-16	Idec Pharma Corp	Anticuerpos recombinantes para terapia humana.
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5686072A (en)	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US7744877B2 (en) *	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
DK0752248T3 (da) *	1992-11-13	2000-11-13	Idec Pharma Corp	Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
PT1974747E (pt)	1998-08-11	2012-09-05	Biogen Idec Inc	Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
ES2543819T3 (es)	1998-11-09	2015-08-24	Biogen Inc.	Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
HK1041811A1 (zh)	1998-11-09	2002-07-26	Idec药物公司	接受bmt或pbsc移植患者的抗cd20嵌合抗体治疗
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU2001259142C1 (en)	2000-04-25	2006-11-23	Biogen Idec Inc.	Intrathecal administration of rituximab for treatment of central nervous system lymphomas
BRPI0315295C1 (pt) *	2002-10-17	2021-05-25	Genmab As	anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) *	2002-12-16	2011-01-11	Genentech Inc	Immunoglobulin variants and uses thereof

1993
- 1993-11-12 DK DK96200772T patent/DK0752248T3/da active
- 1993-11-12 RU RU95112506A patent/RU2139731C1/ru active
- 1993-11-12 EP EP99123967A patent/EP1005870B1/en not_active Expired - Lifetime
- 1993-11-12 PL PL93309002A patent/PL174494B1/pl unknown
- 1993-11-12 RO RO95-00888A patent/RO118524B1/ro unknown
- 1993-11-12 MD MD95-0311A patent/MD1367C2/ro unknown
- 1993-11-12 WO PCT/US1993/010953 patent/WO1994011026A2/en not_active Ceased
- 1993-11-12 NZ NZ258392A patent/NZ258392A/en not_active IP Right Cessation
- 1993-11-12 AU AU56032/94A patent/AU688743B2/en not_active Expired
- 1993-11-12 CA CA002149329A patent/CA2149329C/en not_active Expired - Lifetime
- 1993-11-12 EP EP94901444A patent/EP0669836B1/en not_active Expired - Lifetime
- 1993-11-12 EP EP96200772A patent/EP0752248B1/en not_active Expired - Lifetime
- 1993-11-12 DE DE69303494T patent/DE69303494T2/de not_active Expired - Lifetime
- 1993-11-12 JP JP06512376A patent/JP3095175B2/ja not_active Expired - Lifetime
- 1993-11-12 DK DK94901444.3T patent/DK0669836T3/da active
- 1993-11-12 PL PL93320658A patent/PL174721B1/pl unknown
- 1993-11-12 AT AT94901444T patent/ATE139900T1/de active
- 1993-11-12 ES ES96200772T patent/ES2152483T3/es not_active Expired - Lifetime
- 1993-11-12 AT AT96200772T patent/ATE196606T1/de active
- 1993-11-12 ES ES94901444T patent/ES2091684T3/es not_active Expired - Lifetime
- 1993-11-12 PT PT96200772T patent/PT752248E/pt unknown
- 1993-11-12 DE DE200412000036 patent/DE122004000036I1/de active Pending
- 1993-11-12 DE DE69329503T patent/DE69329503T2/de not_active Expired - Lifetime
1995
- 1995-05-12 FI FI952327A patent/FI112033B/fi not_active IP Right Cessation
- 1995-05-12 NO NO19951903A patent/NO321137B1/no not_active IP Right Cessation
- 1995-06-05 BG BG99701A patent/BG62386B1/bg unknown
- 1995-06-07 US US08/478,967 patent/US5843439A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,813 patent/US6682734B1/en not_active Expired - Lifetime
- 1995-06-07 US US08/476,275 patent/US5776456A/en not_active Expired - Lifetime
- 1995-06-07 US US08/475,815 patent/US6399061B1/en not_active Expired - Lifetime
1996
- 1996-08-07 GR GR960402096T patent/GR3020731T3/el unknown
- 1996-09-17 LV LVP-96-373A patent/LV11732B/en unknown
2000
- 2000-04-21 JP JP2000126317A patent/JP4091235B2/ja not_active Expired - Lifetime
- 2000-12-19 GR GR20000402807T patent/GR3035119T3/el unknown
2001
- 2001-07-17 US US09/905,928 patent/US20030021781A1/en not_active Abandoned
- 2001-07-25 US US09/911,703 patent/US7422739B2/en not_active Expired - Fee Related
- 2001-07-25 US US09/911,692 patent/US7381560B2/en not_active Expired - Fee Related
2004
- 2004-07-16 NL NL300156C patent/NL300156I2/nl unknown
- 2004-07-16 LU LU91089C patent/LU91089I2/fr unknown
- 2004-10-04 US US10/956,039 patent/US20050186205A1/en not_active Abandoned
2006
- 2006-03-07 NO NO20061095A patent/NO329146B1/no not_active IP Right Cessation
- 2006-03-07 NO NO20061094A patent/NO326271B1/no not_active IP Right Cessation
- 2006-05-15 JP JP2006135870A patent/JP4203080B2/ja not_active Expired - Lifetime
- 2006-09-18 NO NO2006011C patent/NO2006011I2/no unknown

Also Published As

Publication number	Publication date
US5843439A (en)	1998-12-01
NO951903L (no)	1995-07-13
ES2152483T3 (es)	2001-02-01
DK0669836T3 (da)	1996-10-14
US20020197255A1 (en)	2002-12-26
NO326271B1 (no)	2008-10-27
US20030095963A1 (en)	2003-05-22
EP0669836B1 (en)	1996-07-03
NL300156I1 (nl)	2004-09-01
LV11732B (en)	1997-10-20
NZ258392A (en)	1997-09-22
EP0752248A1 (en)	1997-01-08
DE122004000036I1 (de)	2005-07-07
PL174721B1 (pl)	1998-09-30
ATE196606T1 (de)	2000-10-15
JP2001010974A (ja)	2001-01-16
LU91089I2 (fr)	2004-09-16
PT752248E (pt)	2001-01-31
DE69303494T2 (de)	1997-01-16
WO1994011026A3 (en)	1994-08-18
NO20061095L (no)	1995-07-13
JP4091235B2 (ja)	2008-05-28
FI952327L (fi)	1995-07-10
BG62386B1 (bg)	1999-10-29
FI112033B (fi)	2003-10-31
EP1005870A3 (en)	2002-10-23
EP1005870A2 (en)	2000-06-07
ES2091684T3 (es)	1996-11-01
NO321137B1 (no)	2006-03-27
AU5603294A (en)	1994-06-08
US7422739B2 (en)	2008-09-09
RU2139731C1 (ru)	1999-10-20
DE69329503D1 (de)	2000-11-02
AU688743B2 (en)	1998-03-19
US5776456A (en)	1998-07-07
EP1005870B1 (en)	2009-01-21
GR3020731T3 (en)	1996-11-30
DK0752248T3 (da)	2000-11-13
FI952327A0 (fi)	1995-05-12
GR3035119T3 (en)	2001-03-30
NO2006011I1 (no)	2006-10-02
DE69329503T2 (de)	2001-05-03
WO1994011026A2 (en)	1994-05-26
LV11732A (lv)	1997-04-20
NO2006011I2 (no)	2011-02-21
JPH08503468A (ja)	1996-04-16
DE69303494D1 (de)	1996-08-08
NO951903D0 (no)	1995-05-12
BG99701A (bg)	1996-02-28
RO118524B1 (ro)	2003-06-30
JP4203080B2 (ja)	2008-12-24
US20030021781A1 (en)	2003-01-30
NO329146B1 (no)	2010-08-30
PL309002A1 (en)	1995-09-18
ATE139900T1 (de)	1996-07-15
PL174494B1 (pl)	1998-08-31
CA2149329C (en)	2008-07-15
MD1367C2 (ro)	2000-11-30
US6682734B1 (en)	2004-01-27
EP0669836A1 (en)	1995-09-06
EP0752248B1 (en)	2000-09-27
US20080089893A9 (en)	2008-04-17
JP3095175B2 (ja)	2000-10-03
NO20061094L (no)	1995-07-13
JP2006262907A (ja)	2006-10-05
CA2149329A1 (en)	1994-05-26
NL300156I2 (nl)	2004-10-01
US6399061B1 (en)	2002-06-04
US7381560B2 (en)	2008-06-03
US20050186205A1 (en)	2005-08-25

Legal Events

Date

Code

Title

Description

1999-06-15

PD99

Pending application

2013-07-31

TC4A

Change of name of proprietor (patent for invention)

Owner name: BIOGEN IDEC INC., US

Free format text: PREVIOUS NAME OF PROPRIETOR: IDEC PHARMACEUTICALS CORPORATION, US

2013-11-12

MK4A

Patent for invention expired

Publication	Publication Date	Title
MD1367B2 (ro)	1999-12-31	Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom
CA2261630C (en)	2012-12-04	Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
MY111961A (en)	2001-03-31	Therapeutic method
RU95112506A (ru)	1998-05-10	Способы лечения, антитела и гибридома
NZ596723A (en)	2013-07-26	Human antibodies that bind human il-12 and methods for producing
TW376320B (en)	1999-12-11	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2284829A1 (en)	1998-10-01	Immunotherapy of b-cell malignancies using anti-cd22 antibodies
AU4399297A (en)	1998-04-24	Reconstituted human anti-hm1.24 antibody
UA48940C2 (uk)	2002-09-16	Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
AU2190997A (en)	1997-09-10	Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
MD1374F2 (ro)	1999-12-31	Anticorpi monoclonali imunostimulatori, procedeu de obtinere a acestora, linii celulare, metoda de tratare a maladiilor si compozitie farmaceutica
EP0504327A4 (en)	1993-06-30	Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
MX9704779A (es)	1997-09-30	Antagonistas de interleukina-5 recombinante, utiles en la preparacion de composiciones para el tratamiento de perturbaciones mediadas por interleukina-5.
EP0198086A4 (en)	1987-03-09	MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY.
GB9009106D0 (en)	1990-06-20	Processes and intermediates for synthetic antibody derivatives
RU2007134368A (ru)	2009-03-27	Способы лечения лимфом с использованием сочетания химиотерапевтического средства и il-2, и, не обязательно, антител анти-cd20
ZA94333B (en)	1994-09-02	Synergistic combination of compound having an antogonist effect on NK1 and on NK2 receptors
EP0194851A3 (en)	1987-07-22	Human tumor therapy
AU2456888A (en)	1989-10-05	Monoclonal antibodies specific for HIV and hybridomas for their production
EP0380542A4 (en)	1990-12-05	Method for treating malignancy and autoimmune disorders in humans
Thierfelder et al.	1995	Immunosuppression by Fc region‐mismatched anti‐T cell antibody treatment
BG51405A1 (en)	1993-05-14	Hybridome cellular line secreting monoclonal antibody ageinst human erythrocytec blood group antigen b
CA2060384A1 (en)	1993-04-16	A pharmaceutical composition containing an antibody recognizing the cdw52 antigen
Maloney	2008	Factors leading to rituximab resistance and how to overcome them
TH9595B (th)	2000-05-31	การใช้ในการรักษาโรคของแอนติบอดีซิเมอริคและแอนติบอดีที่ติดตามได้ด้วยกัมมันตรังสีต่อแอนติเจนที่มีการแบ่งแยกความแตกต่างอย่างจำกัดของลิมโฟไซท์ชนิด b ในมนุษย์ เพื่อการรักษาลิมโฟมาของเซล b